

# **CLINICAL STUDY PROTOCOL**

## **A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Dose Response of Oral CIN-102 in Adults with Idiopathic and Diabetic Gastroparesis**

**Investigational Product:** CIN-102

**Protocol Number:** CIN-102-121

### **Sponsor:**

CinDome Pharma, Inc.

5375 Medpace Way

Cincinnati, OH 45227

United States

██

████████████████████████████████████

**Version Number:** 3.0

**Original Protocol:** 19 May 2019

**Version 2.0, Amendment 1:** 15 Aug 2019

**Version 3.0, Amendment 2:** 13 Nov 2019

### **Confidentiality Statement**

The information in this document is confidential and is not to be disclosed without the written consent of CinDome Pharma, Inc. except to the extent that disclosure would be required by law and for the purpose of evaluating and/or conducting a clinical study for CinDome Pharma, Inc. You are allowed to disclose the contents of this document only to your Institutional Review Board and study personnel directly involved with conducting this protocol. Persons to whom the information is disclosed must be informed that the information is confidential and proprietary to CinDome Pharma, Inc. and that it may not be further disclosed to third parties.

## **SIGNATURE PAGE**

**STUDY TITLE: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Dose Response of Oral CIN-102 in Adults with Idiopathic and Diabetic Gastroparesis**

I, the undersigned, have read this protocol summary of changes and agree that it contains all necessary information required to conduct the study.

Signature

Date

## INVESTIGATOR AGREEMENT

By signing below, I agree that:

I have read this protocol. I approve this document and I agree that it contains all necessary details for carrying out the study as described. I will conduct this study in accordance with the design and specific provision of this protocol and will make a reasonable effort to complete the study within the time designated. I will provide copies of this protocol and access to all information furnished by CinDome Pharma, Inc. to study personnel under my supervision. I will discuss this material with them to ensure they are fully informed about the study product and study procedures. I will let them know that this information is confidential and proprietary to CinDome Pharma, Inc. and that it may not be further disclosed to third parties. I understand that the study may be terminated or enrollment suspended at any time by CinDome Pharma, Inc., with or without cause, or by me if it becomes necessary to protect the best interests of the study subjects.

I agree to conduct this study in full accordance with Food and Drug Administration Regulations, Institutional Review Board/Ethic Committee Regulations and International Council for Harmonisation Guidelines for Good Clinical Practices.

---

Investigator's Signature

---

Date

---

Investigator's Printed Name

## SYNOPSIS

---

**TITLE:** A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Dose Response of Oral CIN-102 in Adults with Idiopathic or Diabetic Gastroparesis

---

**PROTOCOL NUMBER:** CIN-102-121

---

**INVESTIGATIONAL PRODUCT:** CIN-102

---

**PHASE:** 2A

---

**INDICATION:** Treatment and relief of symptoms associated with acute and recurrent gastroparesis

---

**OBJECTIVES:**

The objectives of this study are the following:

- To evaluate the safety and tolerability of multiple doses of CIN-102 in subjects with idiopathic or diabetic gastroparesis
- To evaluate the effect of multiple doses of CIN-102 on gastric emptying as measured by the gastric emptying breath test (GEBT) in subjects with idiopathic or diabetic gastroparesis
- To characterize the pharmacokinetic (PK) of multiple doses of CIN-102 in subjects with idiopathic or diabetic gastroparesis

The exploratory objectives of this study include the following:

- To assess the effect of multiple doses of CIN-102 on nausea associated with gastroparesis based on the nausea score on the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD)
  - To assess the effect of multiple doses of CIN-102 on ANMS GCSI-DD scores (total and subscales) in subjects with idiopathic or diabetic gastroparesis
  - To assess the effect of multiple doses of CIN-102 on a variety of patient reported outcomes
  - To characterize exposure-response relationships of CIN-102
- 

**POPULATION:**

The population for this study is adult subjects 18 to 70 years old with idiopathic gastroparesis or Type 1 or Type 2 diabetes mellitus, according to the American Diabetes Association criteria, and a diagnosis of gastroparesis defined by upper gastrointestinal symptoms felt to be consistent with gastroparesis or previously documented delayed gastric emptying.

---

## STUDY DESIGN AND DURATION:

This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate the safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic or diabetic gastroparesis.

The study will begin by randomizing subjects in Cohort 1 to either CIN-102 [REDACTED] twice daily (BID) or placebo BID in a ratio such that 15 subjects receive CIN-102 and 5 subjects receive placebo. Subjects will opt into either a sparse pharmacokinetic sampling subgroup or an intensive PK sampling subgroup. The study will be stratified at randomization by idiopathic versus diabetic gastroparesis. Efforts will be made to ensure adequate numbers of idiopathic and diabetic gastroparetic subjects are included. After approximately 15 subjects in Cohort 1 complete the study, an independent Data Review Committee (DRC) will convene to review the data from Cohort 1. The independent Data Review Committee will review emerging safety, PK, and/or efficacy data throughout the study to determine if it is safe and appropriate to continue the study with the currently planned dose levels for Cohorts 2 and 3 or if further refinement of the proposed dose levels is warranted. Currently planned dose levels for Cohorts 2 and 3 are [REDACTED] BID and [REDACTED] BID, respectively, with 15 subjects receiving the study drug and 5 subjects receiving placebo in each cohort. However, these planned dose levels may be modified and/or additional cohorts may be added based on emerging information from the current study as well as other ongoing studies. The highest dose will not exceed [REDACTED] BID and no more than 40 additional subjects will be added without a protocol amendment. The DRC will also determine how to advance the cohorts (serially or simultaneously). Further details regarding the role, responsibilities, and procedures of the DRC will be provided in the DRC Charter.

At the Screening Visit, all subjects will sign informed consent prior to any study procedures being performed. Subjects must meet all of the inclusion criteria and none of the exclusion criteria to be eligible for study participation.

Subjects will be evaluated as follows:

- Days -28 to -11: Screening procedures will be performed. [REDACTED]  
[REDACTED]
- Days -10 to -3: [REDACTED] A GEPT will be performed on a single day within this window with breath samples obtained twice prior to consumption of a standardized, <sup>13</sup>C-enriched meal and then at 45, 90, 120, 150, 180, and 240 minutes after meal consumption after an 8-hour fast. [REDACTED]  
[REDACTED]  
[REDACTED]
- Days -3 to -1: A Pre-Randomization visit will be completed to perform safety assessments and to allow adequate turnaround time of lab results prior to Day 1 (Randomization).
- Days 1 to 14: Study drug will be administered (CIN-102 or placebo BID for 14 (±2 days) and safety assessments will be performed; [REDACTED]  
and PK blood sampling will be completed at specified timepoints. [REDACTED]  
[REDACTED]  
[REDACTED]

Note: Day 14 (±2 days): A GEPT will be administered 30 minutes after study drug administration on Day 14 (±2 days). Breath samples will be obtained twice prior to

<sup>13</sup>C-enriched meal consumption and then at 45, 90, 120, 150, 180, and 240 minutes after meal consumption after an 8-hour fast. If a subject withdraws from the study prior to the Day 14 (±2 days) GEBT, attempts should be made to perform a GEBT on the last day of study drug administration.

Subjects will be stratified at randomization based on their etiology for gastroparesis (ie, diabetic gastroparesis versus idiopathic gastroparesis).


On days of the GEBT, subjects will present at the clinic after an overnight fast and should take regular medications, including any treatment for diabetes, with the exception of any prohibited concomitant medication. Diabetic subjects requiring insulin will self-administer their usual morning insulin injection, taking into consideration their fasting status. Subjects will be instructed to bring in their study medication and additional insulin, as needed, to the clinic. Fasting blood glucose will be assessed before study drug administration and gastric emptying assessments to ensure a blood glucose of ≤275 mg/dL. Additional insulin may be given (prorated based on meal caloric content) to ensure a blood glucose of ≤275 mg/dL prior to the gastric emptying procedure. Likewise, Investigators should manage low blood sugar (hypoglycemia; <60 mg/dL) as per their discretion.

Safety will be evaluated through assessments of adverse events, vital signs, physical examinations, clinical laboratory evaluations (including prolactin), and electrocardiogram (ECG) findings. Additionally, a single, optional pharmacogenomic blood sample may be collected at any time during the subject's participation in the study.

Subjects will have follow-up visit(s) 1 to 3 days after the final dose of study drug to assess adverse events, changes to concomitant medications (including use of rescue medications), vital signs, and for PK sampling. Subjects participating in the intensive PK subgroup will be seen in the clinic on Day 15 and Day 16 (+1 day). Subjects participating in the sparse PK subgroup will have the option to complete either the Day 15 Visit or the Day 16 (+1 day) Visit. Unscheduled visits and/or additional follow-up may be required at the discretion of the Investigator. For example, subjects with clinically significant abnormal laboratory findings, unresolved treatment-emergent adverse events, serious adverse events that require follow-up laboratories and review, or clinically significant adverse events may necessitate further assessments.

A study schematic is presented below.

### Study Schematic



\* Anticipated dose level

\*\* For each cohort, patients will be randomized to CIN-102 or placebo. Randomization will occur on the morning of Day 1.

\*\*\*Patients participating in the intensive PK subgroup will be seen in the clinic on Day 15 and Day 16 (+1 day). Patients participating in the sparse PK subgroup will be seen on Day 15 OR Day 16 (+1 day).

BID = 2 times daily; DRC = Data Review Committee; GEBT = gastric emptying breath test.

---

## DOSAGE FORMS AND ROUTE OF ADMINISTRATION:

All subjects will take a dose of blinded study drug (CIN-102 or placebo capsules) orally at [REDACTED] AM [REDACTED] and [REDACTED] PM [REDACTED] [REDACTED]

On Day 14 [ $\pm 2$  days], all subjects will fast for a minimum of 8 hours before the morning dose of study drug and 4 hours following the completion of the GEBT meal. [REDACTED] [REDACTED] Subjects will be provided study drug for self-administration for doses not administered at the site.

---

## EFFICACY VARIABLES:

The primary efficacy variable is the change from baseline (gathered on Days -10 to -3) in gastric emptying as measured by GEBT at Day 14 ( $\pm 2$  days).

The GEBT is a nonradioactive stable isotope breath test, in which the ratio of exhaled  $^{13}\text{CO}_2/^{12}\text{CO}_2$  is used to determine the rate of gastric emptying after consumption of a standardized,  $^{13}\text{C}$ -enriched meal. Subjects will consume a standardized,  $^{13}\text{C}$ -enriched meal after an 8-hour fast at baseline (Days -10 to -3) and after an 8-hour fast starting 30 minutes after study drug administration on Day 14 ( $\pm 2$  days). Breath samples will be obtained twice prior to consumption of a standardized,  $^{13}\text{C}$ -enriched meal and then at 45, 90, 120, 150, 180, and 240 minutes after meal consumption after an 8-hour fast on Days -10 to -3 and Day 14 ( $\pm 2$  days) and 30 minutes after study drug administration on Day 14 ( $\pm 2$  days).

The secondary efficacy variables are the following:

- The change from baseline in gastric emptying as measured by GEBT BT  $T_{1/2}$  (BT  $T_{1/2}$  at Day 14 ( $\pm 2$  days))

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

---

**SAFETY VARIABLES:**

Safety of CIN-102 will be assessed by physical examinations, ECGs, vital sign assessments, clinical laboratory evaluations (including prolactin), and adverse events.

---

**STATISTICAL ANALYSES:**

The Intent-to-Treat Population will include all randomized subjects.

The Modified Intent-to-Treat (MITT) Population will include all randomized subjects who receive at least 1 dose of study drug.

The Per-Protocol (PP) Population will include all subjects in the MITT Population without major protocol violations. Reasons for excluding subjects from the PP Population will be defined and documented in the Statistical Analysis Plan.

The PK Population will include all subjects who receive CIN-102 and have at least 1 quantifiable postdose plasma CIN-102 concentration.

The PK Evaluable Population will include subjects who have sufficient plasma concentration data to characterize at least 1 PK parameter.

---

The Pharmacodynamic Population will include all subjects who receive study drug and have at least 1 postdose prolactin value.

The Safety Population will consist of all randomized subjects who receive any study drug.

The data from placebo subjects of all cohorts will be pooled for efficacy and safety analysis.

[REDACTED]

If the data permit, an attempt will be made to correlate plasma concentration and/or PK parameters with select safety measures, prolactin data, and/or measures of gastric emptying time and symptoms of gastroparesis.

The CIN-102 plasma concentrations and PK parameters will be listed by individual and summarized by treatment for active treatments in tabular format using descriptive statistics. CIN-102 plasma concentrations will be plotted against timepoints by regimen (mean and individual).

Safety data, including physical examinations, ECGs, vital sign assessments, clinical laboratory evaluations (including prolactin), and adverse events, will be summarized by treatment group and time of collection, when appropriate. Individual and mean time course of absolute prolactin values and change from baseline prolactin by treatment may also be generated.

Descriptive statistics (arithmetic mean, standard deviation, median, minimum, and maximum) will be calculated for quantitative safety data, as well as for the difference from baseline, when appropriate. Absolute and change from baseline values in QT (heart rate-corrected QT intervals using Fridericia's formula) will be plotted against timepoints by treatment, if applicable.

Shift tables describing out-of-normal range shifts will be provided for clinical laboratory results.

Safety, PK, and/or efficacy data will be reviewed by an independent DRC while the study is ongoing.

**SAMPLE SIZE DETERMINATION:**

A total of approximately 60 subjects (15 subjects per treatment) will be randomized to CIN-102 [REDACTED] BID, CIN-102 [REDACTED] BID, CIN-102 [REDACTED] BID, or placebo. The sample size is considered adequate to provide the necessary data to evaluate the objectives of the study. No formal statistical assessment for sample size determination has been performed.

---

**SITES:** Up to 20 sites in the United States

---

**SPONSOR:**

CinDome Pharma, Inc.  
5375 Medpace Way  
Cincinnati, OH 45227  
United States

[REDACTED]  
[REDACTED]

---

## TABLE OF CONTENTS

Signature Page .....	2
Investigator Agreement.....	3
Synopsis .....	4
Table of Contents.....	11
List of Tables .....	15
List of Figures .....	16
List of Abbreviations and Definition of Terms.....	17
1 Introduction and Background Information .....	19
1.1 Indication and Treatment Options.....	19
1.2 CIN-102.....	20
1.3 Study Rationale .....	21
1.4 Risk/Benefit.....	21
2 Study Objectives .....	23
2.1 Objectives.....	23
2.2 Exploratory Objectives.....	23
3 Study Description.....	24
3.1 Summary of Study Design .....	24
3.2 Study Indication .....	26
3.3 Dose Escalation and Review Committee .....	26
3.3.1 Criteria for Temporary Suspension of Dosing .....	26
3.3.2 Criteria to Cease Dose Escalation .....	27
4 Selection and Withdrawal of subjects.....	28
4.1 Inclusion Criteria.....	28
4.2 Exclusion Criteria.....	29
4.3 Randomization Criteria .....	31
4.4 Withdrawal Criteria.....	32
5 Study Treatments .....	34
5.1 Treatment Groups.....	34
5.2 Rationale for Dosing .....	34
5.3 Randomization and Blinding.....	35

5.4	Breaking the Blind .....	35
5.5	Drug Supplies .....	35
5.5.1	Formulation and Packaging .....	35
5.5.2	Study Drug Preparation and Dispensing .....	35
5.5.3	Study Drug Administration .....	35
5.5.4	Treatment Compliance .....	36
5.5.5	Storage and Accountability .....	37
5.6	Prior and Concomitant Medications and/or Procedures .....	37
5.6.1	Excluded Medications, Foods, and/or Procedures .....	37
5.6.2	Rescue Medications .....	38
5.6.3	Allowed Medications and/or Procedures .....	38
5.6.4	Documentation of Prior and Concomitant Medication Use .....	38
6	Study Procedures .....	39
6.1	Informed Consent .....	39
6.2	Pharmacogenomic Assessments .....	39
6.3	Screening Visit (Days -28 to -11) .....	39
6.4	Baseline Gastric Emptying Breath Test Visit (Days -10 to -3) .....	40
6.5	Pre-Randomization Visit (Days -3 to -1) .....	40
6.6	Treatment Period – Days 1 to 15 .....	42
6.6.1	Day 1 (Randomization) .....	42
6.6.2	Day 2 .....	43
6.6.3	Day 3 ( $\pm 1$ Day) .....	44
6.6.4	Days 4 to 6 .....	44
6.6.5	Day 7 ( $\pm 1$ Day) .....	45
6.6.6	Days 8 to 9 .....	45
6.6.7	Day 10 ( $\pm 1$ Day) .....	45
6.6.8	Days 11 to 13 .....	46
6.6.9	Day 14 ( $\pm 2$ Days) .....	46
6.6.10	Day 15 .....	48
6.6.11	Follow-up Visit (Day 16 [+ 1 Day]) .....	48
6.7	Early Termination Visit and Withdrawal Procedures .....	49

7	Efficacy Assessments.....	50
7.1	Primary Efficacy Assessment.....	50
7.2	Secondary Efficacy Assessment.....	50
7.3	Exploratory Efficacy Assessment .....	50
7.4	Pharmacokinetics .....	51
7.5	Pharmacogenomic Assessments.....	52
7.5.1	Collection, Storage, and Destruction of Pharmacogenomic Samples .....	52
8	Safety Assessments .....	54
8.1	Adverse Events.....	54
8.1.1	Adverse (Drug) Reaction .....	55
8.1.2	Unexpected Adverse Drug Reaction .....	55
8.1.3	Assessment of Adverse Events by the Investigator .....	55
8.2	Serious Adverse Events.....	56
8.3	Serious Adverse Event Reporting – Procedures for Investigators .....	57
8.4	Pregnancy Reporting .....	58
8.5	Expedited Reporting.....	58
8.6	Clinical Laboratory Evaluations.....	58
8.7	Vital Signs .....	59
8.8	Electrocardiograms.....	59
8.9	Physical Examinations .....	60
8.10	Height and Weight .....	60
9	Statistics .....	61
9.1	Analysis Populations .....	61
9.2	Statistical Methods .....	61
9.2.1	Analysis of Efficacy .....	61
9.2.1.1	Primary efficacy analysis.....	61
9.2.1.2	Secondary efficacy analysis.....	61
9.2.1.3	Exploratory efficacy analysis.....	61
9.2.1.4	Pharmacokinetic analysis.....	62
9.2.1.5	Pharmacokinetic-Pharmacodynamic analysis.....	62

9.2.2	Analysis of Safety .....	62
9.2.3	Interim Analysis .....	62
9.2.4	Sample Size Determination .....	62
10	Data Management and Record Keeping .....	63
10.1	Data Management .....	63
10.1.1	Data Handling .....	63
10.1.2	Computer Systems .....	63
10.1.3	Data Entry .....	63
10.1.4	Medical Information Coding .....	63
10.1.5	Data Validation .....	63
10.2	Record Keeping .....	63
11	Investigator Requirements and Quality Control .....	64
11.1	Ethical Conduct of the Study .....	64
11.2	Institutional Review Board .....	64
11.3	Informed Consent .....	64
11.4	Study Monitoring Requirements .....	64
11.5	Disclosure of Data .....	65
11.6	Retention of Records .....	65
11.7	Publication Policy .....	65
11.8	Financial Disclosure .....	66
12	Study Administrative Information .....	67
12.1	Protocol Amendments .....	67
13	References .....	68
	Appendix A: Schedule of Procedures .....	70
	Appendix B: Clinical Laboratory Analytes .....	74
	Appendix C: Electrocardiogram Alert Criteria Guidance .....	76

## LIST OF TABLES

Table 1.	CTCAE Severity Assessment of Adverse Events.....	55
Table 2.	Schedule of Procedures.....	70

## LIST OF FIGURES

Figure 1. Study Schematic.....	25
--------------------------------	----

## LIST OF ABBREVIATIONS AND DEFINITION OF TERMS

Abbreviation	Definition
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
AUC	Area under the plasma concentration-time curve
AV	Atrioventricular
BID	Twice daily
BMI	Body mass index
BPM	Beats per Minute
BT <sub>1/2</sub>	Gastric Emptying Breath Test t <sub>1/2</sub> (BT t <sub>1/2</sub> )
C <sub>max</sub>	Maximum plasma concentration
CKD-EPI	Chronic Kidney Disease Epidemiology Collaboration
CFR	Code of Federal Regulations
CNS	Central nervous system
CRA	Clinical Research Associate
CTCAE	Common Terminology Criteria for Adverse Events
CYP	Cytochrome P450
DGE	Delayed gastric emptying
DRC	Data Review Committee
ECG	Electrocardiogram
eCRF	Electronic case report form
EDC	Electronic data capture
eGFR	Estimated glomerular filtration rate
EIU	Exposure In Utero
FDA	Food and Drug Administration
FSH	Follicle-stimulating hormone
GCP	Good Clinical Practice
GEBT	Gastric emptying breath test
GI	Gastrointestinal
HBsAg	Hepatitis B surface antigen
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
ICF	Informed consent form
ICH	International Council for Harmonisation
IRB	Institutional Review Board

Abbreviation	Definition
IRT	Interactive Response Technology
IV	Intravenous
LBBB	Left Bundle Branch Block
MAD	Multiple-ascending dose
MITT	Modified Intent-to-Treat
MSEC	Millisecond(s)
PD	Pharmacodynamic(s)
PEG	Percutaneous endoscopic gastrostomy
PGx	Pharmacogenomic
PK	Pharmacokinetic(s)
POC	Point-of-care
PP	Per-Protocol
QTcF	Heart rate-corrected QT interval using Fridericia's formula
SAD	Single-ascending dose
SAE	Serious adverse event
SVT	Supraventricular tachycardia
T <sub>½</sub>	Terminal phase elimination half-life
TSH	Thyroid-stimulating hormone
ULN	Upper limit of normal

## **1 INTRODUCTION AND BACKGROUND INFORMATION**

### **1.1 Indication and Treatment Options**

Gastroparesis is defined as impaired gastric emptying in the absence of physical gastric outlet obstruction. Symptoms include early satiety, postprandial fullness, nausea, vomiting, and abdominal pain.<sup>1</sup> The disease is often associated with diabetes or may occur after gastric surgery; it may also be idiopathic from unknown etiologies.<sup>2</sup> Gastroparesis affects the patient's nutritional state, especially in diabetics, and severe symptoms of gastroparesis can lead to other complications such as malnutrition, esophagitis, and Mallory-Weiss tears.<sup>3,4</sup> Gastroparesis negatively impacts a patient's quality of life, causing decreased social interaction, poor work functionality, and development of anxiety or depression.<sup>3</sup>

The first-line treatment for gastroparesis involves nutritional management and support, including fluid and electrolyte replacement. Pharmacologic therapy is directed at increasing gastric emptying and accelerating intestinal transit time. Currently, metoclopramide, a dopamine D<sub>2</sub> receptor antagonist, is the only United States Food and Drug Administration (FDA)-approved agent for the treatment of gastroparesis. While effective, this agent readily crosses the blood-brain barrier resulting in central nervous system (CNS) side effects in up to 40% of patients.<sup>5</sup> Common CNS effects associated with metoclopramide treatment include restlessness, drowsiness, fatigue, and lassitude; however, the major safety concern with metoclopramide treatment is the development of tardive dyskinesia. Tardive dyskinesia is a disorder characterized by involuntary movements of the face, tongue, or extremities and is often irreversible. Increased risk of developing tardive dyskinesia correlates to treatment duration; therefore, it is recommended that therapy with metoclopramide not exceed 12 weeks.<sup>6</sup>

Domperidone is a peripheral dopamine D<sub>2</sub> receptor antagonist that acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone in the area postrema and the motor function in the stomach and small intestine.<sup>7,8</sup> Domperidone has been available worldwide outside of the United States since 1978 as a treatment for gastroparesis as well as a general antiemetic. It is currently available in 58 countries, including Canada. In those countries where domperidone is approved, the current recommended daily dose is up to 30 mg/day (10 mg administered orally 3 times a day) for nausea and vomiting. While available in many countries worldwide, domperidone is only available to patients in the United States through a physician-initiated Investigational New Drug application at doses up to 120 mg/day (30 mg administered orally 4 times per day) for the treatment of gastroparesis and any condition causing chronic nausea and vomiting.<sup>8</sup> Current treatment guidelines recommend the use of domperidone for patients unable to use metoclopramide.<sup>9</sup>

Unlike metoclopramide, domperidone does not cross the blood-brain barrier and seldom causes extrapyramidal side effects. Similar to other dopamine D<sub>2</sub> receptor antagonists, domperidone has been shown to raise prolactin levels with chronic administration, but prolactin levels return to normal upon discontinuation of the drug.<sup>7,10</sup> Use of domperidone has also been associated with QT prolongation. Due to reports of cardiac arrest with the use of intravenous (IV) domperidone, the IV dose form was removed from the market. Given the low oral bioavailability of domperidone (approximately 13% to 17% of the administered dose),<sup>8</sup> oral doses in excess of 1000 mg/day would correlate with the IV doses administered to patients at the time when the cardiac issues were reported.<sup>11</sup> When QT prolongation has been reported with oral domperidone, it has primarily been in patients over 60 years of age, in patients taking more than 30 mg/day, in patients with cardiac

predispositions, or in patients who were also receiving other QT-prolonging drugs or potent cytochrome P450 (CYP) 3A4 inhibitors, such as ketoconazole. However, there have been reports of cases of QT prolongation among patients taking domperidone with none of these additional risk factors.<sup>12,13</sup> The potential for QT prolongation is believed to be related to increased plasma concentrations of domperidone. It is suggested that the mean effect on QT of  $\geq 10$  msec (the definition of QT prolongation) may occur when the domperidone plasma concentration reaches approximately 65 ng/mL.<sup>14,15</sup> Therefore, limiting the maximum plasma concentration ( $C_{max}$ ) of domperidone to approximately 60 ng/mL may significantly lower the risk of QT prolongation.

## 1.2 CIN-102

CinDome Pharma, Inc. is currently developing CIN-102, a deuterated form of domperidone. A new process was developed to synthesize a deuterated version of domperidone [REDACTED]

[REDACTED] Given that the pharmacological properties of CIN-102 are similar to those of domperidone, CIN-102 is intended to provide an alternative for the treatment and relief of symptoms associated with acute and recurrent gastroparesis that may have less potential for QT prolongation.

Two clinical studies of CIN-102 in healthy subjects have commenced to date: a single-ascending dose (SAD) study ([Study CIN-102-111](#)) and a multiple-ascending dose (MAD) study ([Study CIN-102-112](#)). [REDACTED]

### 1.3 Study Rationale

To date, the PK, pharmacodynamics (PD; based on increases in prolactin), and safety of CIN-102 have been evaluated in a SAD study and a MAD study in healthy subjects. The current study is the first study in subjects with gastroparesis. As such, this study is intended to evaluate the effect of CIN-102 on gastric emptying in subjects with idiopathic or diabetic gastroparesis over a range of doses. The safety, PK, and effect of CIN-102 on symptoms of gastroparesis in these subjects will also be assessed in this proof of concept study. The results of this study will be used to support dose selection for future studies.

### 1.4 Risk/Benefit

Side effects that have been reported by  $\geq 1\%$  of subjects treated in clinical trials with domperidone with a median total daily dose of 80 mg include the following: depression, anxiety, loss of libido, headache, somnolence, akathisia, diarrhea, rash, pruritus, gynecomastia, breast tenderness, galactorrhea, amenorrhea, breast pain, irregular menstruation, lactation disorders, and asthenia.<sup>7</sup> Less frequently reported adverse events that occurred in  $<1\%$  of treated subjects include hypersensitivity, urticaria, breast discharge, and breast swelling.<sup>7</sup> Rare or very rare adverse reactions that have been estimated from spontaneous reporting include anaphylactic reactions, agitations, nervousness, extrapyramidal disorders, convulsions, sudden cardiac death, ventricular arrhythmias, angioedema, urinary retention, abnormal liver tests, and increased blood prolactin.<sup>7</sup>

As noted previously, domperidone has been associated with prolongation of the QT interval on electrocardiograms (ECGs).<sup>16</sup> During postmarketing surveillance, there have been very rare cases ( $<1/10,000$  cases) of QT prolongation and QT prolongation-induced Torsades de pointes in patients taking oral domperidone.<sup>16,17</sup> These reports included patients with confounding risk factors, electrolyte abnormalities, and concomitant treatment, which may have been contributing factors.<sup>17</sup> Epidemiological studies showed that domperidone was associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death.<sup>16</sup> A higher risk was observed with IV administration and following oral administration in patients older than 60 years, patients taking total daily oral doses greater than 30 mg, and patients concurrently taking QT-prolonging drugs or CYP3A4 inhibitors.<sup>11,12</sup> However, there have been reports of cases of QT prolongation in patients taking domperidone with none of these additional risk factors.<sup>12,13</sup> From a review of the literature, including an assessment of the thorough QT and case-controlled studies with respect to the incidence of QT prolongation and sudden cardiac death, the data appear to indicate that the risk of QT prolongation is related to the increased plasma levels of domperidone.<sup>11,14,18</sup> Additionally, the FDA Expanded Access to Investigational Drugs program website for requesting domperidone indicates that the serious risks associated with domperidone are related to domperidone levels in the blood, and higher domperidone blood levels are associated with higher risk of these events.<sup>19</sup>

Other study-related risks include those associated with blood draws, such as discomfort, bruising, infection, bleeding, pain, redness at the puncture site, and/or lightheadedness, as well as temporary

discomfort, redness, or rash at the site of ECG electrode placement, and dizziness, headache, stomach discomfort, or fainting due to fasting.

The doses planned for inclusion in this study were chosen based upon the safety, tolerability, and PK profile established in the Phase 1 SAD and MAD studies. The mean  $C_{\max}$  of 48.18 ng/mL observed in healthy subjects receiving 60 mg BID (the highest proposed dosing regimen for the current study) is below the highest observed mean  $C_{\max}$  from the 120 mg single dose (96.8 ng/mL), a dose that was well-tolerated by healthy subjects with no clinically meaningful QT prolongation. Given the association of QT prolongation and domperidone, subjects participating in this study will be monitored closely for adverse events, including those that have been reported with domperidone, and 12-lead ECGs will be collected at each visit to the clinic.

A goal of this study is to assess the effect of CIN-102 on gastric emptying in subjects with idiopathic or diabetic gastroparesis. Given the known antiemetic and prokinetic effects of domperidone, it is possible that subjects may experience improvement in their symptoms during the course of this study.

## **2 STUDY OBJECTIVES**

### **2.1 Objectives**

The objectives of this study are the following:

- To evaluate the safety and tolerability of multiple doses of CIN-102 in subjects with idiopathic or diabetic gastroparesis
- To evaluate the effect of multiple doses of CIN-102 on gastric emptying as measured by the gastric emptying breath test (GEBT) in subjects with idiopathic or diabetic gastroparesis
- To characterize the PK of multiple doses of CIN-102 in subjects with idiopathic or diabetic gastroparesis

### **2.2 Exploratory Objectives**

The exploratory objectives of this study include the following:

- To assess the effect of multiple doses of CIN-102 on nausea associated with gastroparesis based on the nausea score on the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD)
- To assess the effect of multiple doses of CIN-102 on ANMS GCSI-DD scores (total and subscales) in subjects with idiopathic or diabetic gastroparesis
- To assess the effect of multiple doses of CIN-102 on a variety of patient reported outcomes
- To characterize exposure-response relationships of CIN-102

### 3 STUDY DESCRIPTION

#### 3.1 Summary of Study Design

This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic or diabetic gastroparesis.

The study will begin by randomizing subjects in Cohort 1 to either CIN-102 [REDACTED] BID or placebo BID in a ratio such that 15 subjects receive CIN-102 and 5 subjects receive placebo. Subjects will opt into either a sparse pharmacokinetic sampling subgroup or an intensive PK sampling subgroup. The study will be stratified at randomization by idiopathic versus diabetic gastroparesis. Efforts will be made to ensure adequate numbers of idiopathic and diabetic gastroparetic subjects are included. After approximately 15 subjects in Cohort 1 complete the study, an independent Data Review Committee (DRC) will convene to review the data from Cohort 1. The Data Review Committee will review emerging safety, PK, and/or efficacy data throughout the study to determine if it is safe and appropriate to continue the study with the currently planned dose levels for Cohorts 2 and 3 or if further refinement of the proposed dose levels is warranted. Currently planned dose levels for Cohorts 2 and 3 are [REDACTED] BID and [REDACTED] BID, respectively, with 15 subjects receiving the study drug and 5 subjects receiving placebo in each cohort. However, these planned dose levels may be modified and/or additional cohorts may be added based on emerging information from the current study as well as other ongoing studies. The highest dose will not exceed [REDACTED] BID and no more than 40 additional subjects will be added without a protocol amendment. The DRC will also determine how to advance the cohorts (serially or simultaneously). Further details regarding the role, responsibilities, and procedures of the DRC will be provided in the DRC Charter.

At the Screening Visit, all subjects will sign informed consent prior to any study procedures being performed. Subjects must meet all of the inclusion criteria and none of the exclusion criteria to be eligible for study participation.

Subjects will be evaluated as follows:

- Days -28 to -11: Screening procedures will be performed. [REDACTED]  
[REDACTED]
- Day -10 to -3: [REDACTED] A GEBT will be performed on a single day within this window with breath samples obtained twice prior to consumption of a standardized, <sup>13</sup>C-enriched meal and then at 45, 90, 120, 150, 180, and 240 minutes after meal consumption after an 8-hour fast. [REDACTED]  
[REDACTED]  
[REDACTED]
- Day -3 to -1: A Pre-Randomization visit will be completed to perform safety assessments and to allow adequate turnaround time of lab results prior to Day 1 (Randomization).
- Days 1 to 14: Study drug will be administered (CIN-102 or placebo BID for 14 (±2 days) and safety assessments will be performed; [REDACTED]  
and PK blood sampling will be completed at specified timepoints. [REDACTED]  
[REDACTED]  
[REDACTED].

Note: Day 14 ( $\pm 2$  days): A GEBT will be administered 30 minutes after study drug administration on Day 14 ( $\pm 2$  days). Breath samples will be obtained twice prior to  $^{13}\text{C}$  enriched meal consumption and then at 45, 90, 120, 150, 180, and 240 minutes after meal consumption after an 8-hour fast. If a subject withdraws from the study prior to the Day 14 ( $\pm 2$  days) GEBT, attempts should be made to perform a GEBT on the last day of study drug administration. [REDACTED]

Subjects will be stratified at randomization based on their etiology for gastroparesis (ie, diabetic gastroparesis versus idiopathic gastroparesis).


On days of the GEBT, subjects will present at the clinic after an overnight fast and should take regular medications, including any treatment for diabetes, with the exception of any prohibited concomitant medication. Subjects will self-administer their usual morning insulin injection, taking into consideration their fasting status. Subjects will be instructed to bring in their study medication and additional insulin, as needed, to the clinic. Fasting blood glucose will be assessed before study drug administration and gastric emptying assessments to ensure a blood glucose of  $\leq 275$  mg/dL. Additional insulin may be given (prorated based on meal caloric content) to ensure a blood glucose of  $\leq 275$  mg/dL prior to the gastric emptying procedure. Likewise, Investigators should manage low blood sugar (hypoglycemia;  $< 60$  mg/dL) as per their discretion.

Safety will be evaluated through assessments of adverse events, vital signs, physical examinations, clinical laboratory evaluations (including prolactin), and ECG findings. Additionally, a single, optional pharmacogenomic (PGx) blood sample may be collected at any time during the subject's participation in the study.

Subjects will have follow-up visit(s) 1 to 3 days after the final dose of study drug to assess adverse events, changes to concomitant medications (including use of rescue medications), vital signs, and for PK sampling. Subjects participating in the intensive PK subgroup will be seen in the clinic on Day 15 and Day 16 (+1 day). Subjects participating in the sparse PK subgroup will have the option to complete either the Day 15 Visit or the Day 16 (+1 day) Visit. Unscheduled visits and/or additional follow-up may be required at the discretion of the Investigator. For example, subjects with clinically significant abnormal laboratory findings, unresolved treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) that require follow-up laboratories and review, or clinically significant adverse events may necessitate further assessments.

Figure 1 presents a study schematic.

**Figure 1. Study Schematic**



\* Anticipated dose level

\*\* For each cohort, patients will be randomized to CIN-102 or placebo. Randomization will occur on the morning of Day 1.

\*\*\*Patients participating in the intensive PK subgroup will be seen in the clinic on Day 15 and Day 16 (+1 day). Patients participating in the sparse PK subgroup will be seen on Day 15 OR Day 16 (+1 day).

BID = 2 times daily; DRC = Data Review Committee; GEFT = gastric emptying breath test.

### **3.2 Study Indication**

CIN-102 is being developed for the treatment and relief of symptoms associated with acute and recurrent gastroparesis.

### **3.3 Dose Escalation and Review Committee**

A DRC consisting of at least three members, including a cardiologist, a clinical pharmacologist, and an independent clinician experienced in the treatment of patients with idiopathic or diabetic gastroparesis will be formed to review emerging PK and safety data in a blinded manner.

The DRC will convene to review safety and efficacy data through at least Day 14 from approximately 15 of the subjects in each cohort. PK data from approximately 8 subjects receiving CIN-102 in each cohort will be considered adequate for DRC review (these PK data may be a combination of the sparse PK scheme and the intense PK from a subset of subjects). In the event a subject discontinues the study at least 24 hours after steady-state is believed to have been achieved (based on available data from the SAD and MAD studies) for a reason unrelated to safety, the existing data from that individual may be sufficient for decision making by the DRC.

Dose escalation will only take place after the DRC has determined that is appropriate (eg, adequate safety and tolerability have been demonstrated and PK behavior is well enough characterized to support proceeding to a higher dose level and/or study of a lower dose level or frequency is meaningful based on emerging safety data).

Upon each DRC review, the following may occur:

- proceed to the next protocol-specified dose level or
- proceed to alternate dosing regimen(s) not to exceed the next protocol-specified dose level

Further detail on DRC conduct will be described in the DRC Charter.

#### **3.3.1 Criteria for Temporary Suspension of Dosing**

Dosing within a cohort or between cohorts will be temporarily suspended until a full cumulative data review is complete if any of the following occur:

- Any study drug-related SAE grade 3 or higher based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
- Any single subject whose ECG (average triplicate ECGs as interpreted by central read) demonstrates a heart-rate corrected QTcF interval (QTcF) >500 msec or in whom there is an increase in QTcF >60 msec from baseline (confirmed by repeat ECG)
- Any new ECG abnormality deemed clinically significant by the investigator
- Any study drug-related cardiac adverse event. In the event that a subject experiences a vasovagal or near-syncopal episode, dosing within a cohort or subsequent cohort may proceed as planned unless the episode is associated with ECG abnormality or the event is deemed to be severe in intensity (severity) by the Investigator
- A study drug-related adverse event from a single System Organ Class deemed to be of moderate intensity (severity) in 4 or more subjects

- Any of the following laboratory abnormalities that are thought to be study drug-related or in which an alternative explanation is not reasonable:
  - ALT or AST  $>8 \times$  the upper limit of normal (ULN), or
  - ALT or AST  $>5 \times$  ULN and persist for more than 2 weeks, or
  - ALT or AST  $>3 \times$  ULN in conjunction with elevated total bilirubin  $>2 \times$  ULN or international normalized ratio  $>1.5$ , or
  - ALT or AST  $>3 \times$  ULN with appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia ( $>5\%$ )
- Any single subject who develops serious study drug-related electrolyte abnormalities due to vomiting and/or inability to maintain adequate oral hydration that impacts cardiac stability
- Other conditions as deemed medically appropriate based on the Investigator's judgement

The Sponsor and/or DRC may also suspend dosing for any other reason based on emerging data. Should dosing be temporarily suspended, the DRC can review and discuss all available safety and PK data from all subjects participating in the study up until the time of the event. The DRC will decide whether knowledge of the treatment assignment of any subject(s) is(are) necessary to make an appropriate decision about continuation of the study. If so, a request to unblind will be made and relevant data will be reviewed in an unblinded manner. All unblinding Standard Operating Procedures will be followed and documented as appropriate.

Upon completion of the cumulative data review (whether fully blinded or partially unblinded), the DRC may elect to terminate the study or to resume study conduct. If study conduct is resumed, the DRC may elect to do one of the following:

- Continue dosing in the current cohort with the same number of subjects originally planned
- Expand the current cohort with additional subjects to obtain more information at that dose level
- Escalate to a higher dose level
- Increase the frequency of dosing at the current dose level (if the protocol-specified number of subjects at the current dose level have already completed)
- De-escalate to a lower dose level
- Decrease the frequency of dosing at the current dose level

### 3.3.2 Criteria to Cease Dose Escalation

Dosing within a cohort or between cohorts will cease if either of the following occurs:

- Any two grade 3 or 1 grade 4 or higher study drug-related SAE based on CTCAE Version 5.0
- Any 2 subjects with an ECG (average of triplicate ECGs as determined by central read) demonstrating QTcF  $>500$  msec or a change in QTcF  $>60$  msec from baseline (confirmed by repeat ECG with central read)

Should one of the above occur, consideration may still be given to continued study of an alternate dose level or frequency (either expansion of a previously studied cohort or addition of a lower dose level).

## **4 SELECTION AND WITHDRAWAL OF SUBJECTS**

### **4.1 Inclusion Criteria**

Patients who meet all of the following criteria will be eligible to participate in the study:

1. Male and female patients 18 to 70 years old.
2. Has a current diagnosis of idiopathic or diabetic gastroparesis as defined by the following:
  - Has gastrointestinal (GI) symptoms felt to be consistent with gastroparesis (eg, postprandial nausea/vomiting, postprandial fullness, early satiety, bloating, and/or epigastric/abdominal pain) within the 6 months prior to screening;
  - OR
  - Has documented delayed gastric emptying (DGE) within the past 3 years as determined by GEBT or scintigraphy. Patients who have DGE documented through other modalities (eg, SmartPill, manometry, etc) or who have had an abnormal GEBT or scintigraphy >3 years ago may be considered with Sponsor approval.
3. Has a body mass index (BMI) between 18 and 40 kg/m<sup>2</sup>, inclusive.
4. Has glycosylated hemoglobin level ≤11% at Screening.
5. Male patients with female partners of child-bearing potential must agree to use 2 medically accepted, highly effective methods of birth control from Day 1 through 60 days following the final dose of study drug.
  - Medically accepted, highly effective methods of birth control for male patients with female partners of child-bearing potential include the following: latex condom with spermicide, diaphragm with intravaginal spermicide, cervical cap with spermicide, indwelling intrauterine device (hormonal or nonhormonal), implanted contraceptives, and oral contraceptives.
6. Male patients must agree to abstain from sperm donation from Day 1 through 60 days following the final dose of study drug.
7. Female patients with male partners must be surgically sterile (hysterectomy and/or bilateral oophorectomy), postmenopausal for at least 1 year (with confirmed follicle-stimulating hormone [FSH] in postmenopausal range at the Screening Visit), or agree to use 2 medically accepted, highly effective methods of birth control from Day -14 until 60 days following the final dose of study drug.
  - Medically accepted, highly effective methods of birth control for female patients with male partners include the following: latex condom with spermicide, diaphragm with intravaginal spermicide, cervical cap with spermicide, and nonhormonal indwelling intrauterine device.
8. Has a negative breath alcohol and urine drug screen (including tetrahydrocannabinol) at the Screening Visit and at the time of randomization.

9. Is willing to abstain from grapefruit, grapefruit products, star fruit, star fruit products, and Seville oranges from 48 hours prior to randomization until end of study.

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
11. Is able to understand and willing to comply with all study visits, procedures, restrictions, discontinuation of medications, including those to treat gastroparesis (as specified in the protocol), and provide written informed consent according to institutional and regulatory guidelines.

#### **4.2 Exclusion Criteria**

Patients who meet any of the following criteria will be excluded from participation in the study:

1. Has a history of, or current, clinically significant arrhythmias as judged by the Investigator, including ventricular tachycardia, ventricular fibrillation, and Torsades de pointes. Patients with minor forms of ectopy (eg, premature atrial contractions) are not necessarily excluded, per Investigator discretion.
2. Has clinically significant bradycardia with a resting heart rate under 50 beats per minute, sinus node dysfunction, or heart block.
3. Has prolonged heart rate-corrected QT interval using Fridericia's formula (QTcF) (QTcF >450 msec for males or QTcF >470 msec for females) based on the average of triplicate ECGs.
4. Has a personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias or family history of sudden death.
5. Has evidence (based on screening or baseline assessments) or history of clinically significant immunologic, hematologic, renal, endocrine, pulmonary, GI, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies); surgical conditions; cancer (with the exception of basal or squamous cell carcinoma of the skin and cancer that resolved or has been in remission for >5 years prior to the Screening Visit); or any condition that, in the Investigator's opinion, might significantly interfere with the absorption, distribution, metabolism, or excretion of the study drug.  
Note: Cholecystectomy and appendectomy are allowed.
6. Has a history of prolactin-releasing pituitary tumor (ie, prolactinoma).
7. Has elevated serum prolactin.

Note: Patients who are on medications that are known to increase prolactin (eg, domperidone, metoclopramide, phenothiazines, SSRIs, verapamil, etc) with an elevated prolactin at the time of screening may be considered for this study.

8. Has known or suspected hypogonadism, current clinically significant menstrual abnormalities (eg, oligomenorrhea or amenorrhea), gynecomastia, galactorrhea, or other clinical features that in the Investigator's opinion may be consistent with hyperprolactinemia.
9. Has pyloric injection of botulinum toxin within 6 months of screening and/or during the course of the study.
10. Has bilirubin, alkaline phosphatase, aspartate aminotransferase (AST), or alanine aminotransferase (ALT) levels greater than  $2 \times$  the upper limit of normal or has a Child-Pugh classification grade of B or C.
11. Has a serum creatinine level greater than  $1.5 \times$  the upper limit of normal or has an estimated glomerular filtration rate (eGFR)  $<30$  mL/min/1.73 m<sup>2</sup> using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at screening.
12. Has a hemoglobin level  $<10$  g/dL at screening.
13. Has thyroid-stimulating hormone (TSH) levels that are abnormal at screening, as judged by the Investigator.
14. Has inability to perform a breath test.
15. Has known allergy to eggs or spirulina.
16. Use of investigational, prescription, or over-the-counter medications as follows:
  - Actively participating in an experimental therapy study; received experimental therapy with a small molecule within 30 days of randomization or 5 half-lives (whichever is longer); or received experimental therapy with a large molecule within 90 days of randomization or 5 half-lives, (whichever is longer).

- [REDACTED]
  - [REDACTED]
  - [REDACTED]
  - [REDACTED]
  - [REDACTED]
  - [REDACTED]
17. History of alcoholism or drug abuse within 2 years prior to dosing as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition.
18. Typical consumption of  $\geq 14$  alcoholic drinks weekly.

19. Evidence of ongoing illicit drug use.
20. Positive for human immunodeficiency virus (HIV) antibody, hepatitis C virus (HCV) by RNA, or hepatitis B surface antigen (HBsAg) at the Screening Visit.
21. Donated blood or blood products within 30 days prior to dosing.
22. Currently undergoing treatment with weight loss medication or prior weight loss surgery (eg, gastric bypass surgery).
23. Pregnant, breastfeeding, or planning to become pregnant during the course of study.
24. Inability to swallow medication.
25. Currently receiving parenteral feeding or presence of a nasogastric or other enteral tube (eg, percutaneous endoscopic gastrostomy [PEG] tube) for feeding or decompression.
26. Known or suspected gastric outlet obstruction (eg, peptic stricture) or other GI mechanical obstruction as documented by upper GI tract endoscopy or upper GI radiographic series in the past 3 years.
27. Known history or current diagnosis of intestinal malabsorption or pancreatic exocrine disease.
28. History of gastric surgery such as fundoplication, gastrectomy, vagotomy, pyloroplasty, or bariatric procedure.

Note: Patients who have a gastric pacemaker in place may be considered for the study if the pacemaker can be turned off for at least 14 days prior to baseline GEBT and throughout the remainder of the study.

Note: A history of diagnostic endoscopy is not exclusionary. Cholecystectomy and appendectomy are allowed.

29. History or presence of any medical condition or psychiatric disease, which, in the opinion of the Investigator, could interfere with the conduct of the study or would put the patient at unacceptable risk.
30. Prior lack of response to domperidone or known hypersensitivity or intolerance to domperidone or any of the excipients in the CIN-102 formulation.
31. Judged by the Investigator, after reviewing medical and psychiatric history, physical examination, and laboratory evaluation, to be unsuitable for any other reason that may either place the patient at increased risk during participation or interfere with the interpretation of the study outcomes.

### **4.3 Randomization Criteria**

In addition to the general criteria listed in [Sections 4.1](#) and [4.2](#), in order to be randomized into the study, subjects must also meet the following criteria at the time of randomization:

- Continues to satisfy all inclusion/exclusion criteria.
- Has been off all motility agents and antiemetics for at least 14 days and is willing to remain off such medications (except for protocol-specified antiemetic rescue medication) during the course of the study.

- Demonstrates a confirmed diagnosis of idiopathic or diabetic gastroparesis as defined by the following:
  - Current upper GI symptoms (eg, nausea/vomiting, postprandial fullness, early satiety, bloating, and/or epigastric/ abdominal pain).
  - Documented DGE within the 10 days prior to first dose of study drug based on GEBT using  $^{13}\text{C}$ -spirulina platensis demonstrating  $T_{1/2} > 80$  minutes. Subjects with a  $T_{1/2} > 200$  minutes may be considered for the study with sponsor approval.<sup>20</sup>

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

- Has continued required results of the initial safety laboratory test performed at Screening.

#### 4.4 Withdrawal Criteria

Participation of a subject in this clinical study may be discontinued for any of the following reasons:

- Subject withdraws consent or requests discontinuation from the study for any reason.
- Occurrence of any medical condition or circumstance that exposes the subject to substantial risk and/or does not allow the subject to adhere to the requirements of the protocol.
- Any SAE, clinically significant adverse event, severe laboratory abnormality, clinically significant change in ECG from baseline (eg, QTcF > 500 msec, change in QTcF > 60 msec from baseline (confirmed by repeat ECG with central interpretation), etc.), new ECG abnormality deemed clinically significant by the investigator, intercurrent illness, or other medical condition which indicates to the Investigator that continued participation is not in the best interest of the subject.
- Pregnancy.
- Requirement of prohibited concomitant medication.
- Subject failure to comply with protocol requirements or study-related procedures.
- Termination of the study by the Sponsor or the regulatory authority.

If a subject withdraws prematurely from the study due to the above criteria or any other reason, study staff should make every effort to complete the full panel of assessments scheduled for the Early Termination Visit. The reason for subject withdrawal must be documented in the electronic case report form (eCRF).

Study enrollment will continue until 60 subjects (15 subjects per treatment) have completed the treatment period. Withdrawn subjects will not be replaced.



### 5.3 Randomization and Blinding

Subjects who have completed the Screening Visit and meet all of the inclusion, none of the exclusion criteria, and all of the additional criteria based on randomization procedures, including safety laboratory tests (see [Section 6.5](#)), will be randomized into the study. Randomization will occur on Day 1. Randomization assignments will be provided by [REDACTED] (IRT). Following randomization, study drug will be dispensed in a double-blind manner on Day 1. The Sponsor and all clinical personnel will be blinded to the treatment group for each subject. Subjects will also be blinded to the treatment they receive.

Subjects will be stratified at randomization based on their etiology for gastroparesis (ie, diabetic gastroparesis versus idiopathic gastroparesis).

Bioanalytical staff involved in analysis of PK samples will be unblinded to treatment either via receipt of the randomization code to allow for analysis of samples from subjects receiving CIN-102 only (and possibly limited analysis of samples from subjects receiving placebo), or by the nature of the results of sample analysis. The PK data will be de-identified before being provided to any other individuals, including those involved in calculating PK parameters and associated descriptive statistics, performing any modelling or simulations, and/or plotting PK data, in order to maintain blinding.

### 5.4 Breaking the Blind

Blinding is not to be broken during the study unless considered necessary by the Investigator for emergency situations for reasons of subject safety. Unblinding at the site for any other reason will be considered a protocol deviation. The Investigator should contact the Medical Monitor before breaking the blind, if time permits. When the blind is broken, the reason must be fully documented. The Investigator will be informed of treatment assignment via [REDACTED] IRT.

### 5.5 Drug Supplies

#### 5.5.1 Formulation and Packaging

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

#### 5.5.2 Study Drug Preparation and Dispensing

CIN-102 and matching placebo capsules will be provided to the site by the Sponsor or designee.

#### 5.5.3 Study Drug Administration

All subjects will take a dose of blinded study drug (CIN-102 or placebo capsules) orally at [REDACTED] AM [REDACTED] and [REDACTED] PM [REDACTED]

[REDACTED]

Subjects will be provided study drug for self-administration for doses not administered at the site.

In the event that the subject vomits after taking their scheduled dose of study drug, subjects will be instructed to note the time of study drug administration and time of vomiting and to resume their assigned dose of study drug at the next scheduled time. During the treatment period, subjects should attempt to note the time of vomiting in relation to time of study drug administration and report this to site staff during scheduled clinic visits.

Study drug will be administered at the site by site staff during subject confinement and at all outpatient visits. A hand and mouth check will be performed by site staff to ensure study drug compliance. Dosing compliance will be recorded by the Investigator or designee at the site. The date and time of study drug administration will be recorded.

If a subject withdraws from the study or does not comply with the study protocol procedures, the subject can cease participation in the study but will still be considered evaluable for safety purposes. If a subject withdraws from the study or does not comply with the protocol after receiving study drug but before Day 14 procedures have been performed, they will be requested to undergo the Early Termination procedures.

#### 5.5.5 Storage and Accountability

Records will be maintained indicating the receipt and dispensation of all study drug supplies. At the conclusion of the study, any unused study drug will be returned to the Sponsor or designee for final drug accountability and destruction. A certificate of destruction will be provided. If no study drug remains, this will be indicated in the Drug Accountability Log.

[REDACTED]

### 5.6 Prior and Concomitant Medications and/or Procedures

#### 5.6.1 Excluded Medications, Foods, and/or Procedures

Use of the following investigational, prescription, or over-the-counter medications is not permitted during the study:

- [REDACTED]
- [REDACTED]

- Experimental therapy with a small molecule within 30 days prior to randomization or 5 half-lives (whichever is longer); or experimental therapy with a large molecule within 90 days prior to randomization or 5 half-lives (whichever is longer).

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] should be turned off within 14 days prior to baseline GEBT and kept off until end of study.

- Pyloric injection of botulinum toxin within 6 months of screening and during the course of the study.
- Weight loss medication or prior weight loss surgery (eg, gastric bypass surgery).
- Parenteral feeding or presence of a nasogastric or other enteral tube (eg, PEG tube) for feeding or decompression.

#### 5.6.2 Rescue Medications

[REDACTED]  
[REDACTED]  
[REDACTED] Subjects who require further treatment with prohibited medications may be discontinued from study treatment (at discretion of the Investigators and in consult with the Sponsor's Medical Monitor) and undergo follow-up study procedures.

#### 5.6.3 Allowed Medications and/or Procedures

Other medications that are not explicitly and previously excluded are permitted (eg, rescue medications in accordance with Section 5.6.2) after approval from the Investigator.

#### 5.6.4 Documentation of Prior and Concomitant Medication Use

Any medications administered 28 days prior to the first dose of study drug and/or during the study period must be recorded.

## **6 STUDY PROCEDURES**

### **6.1 Informed Consent**

Written informed consent for the study will be obtained from all subjects before any study procedures are performed. See [Section 11.3](#) for details on informed consent.

### **6.2 Pharmacogenomic Assessments**

A single, optional PGx blood sample may be collected at any time during the subject's participation in the study. In order to have a PGx sample collected, subjects must provide written informed consent to participate, which is included in the main informed consent form (ICF). The subject may withdraw consent to participate in the PGx assessment at any time during the study without withdrawing consent to participate in the study. See [Section 7.5](#) for additional details on the PGx assessments.

### **6.3 Screening Visit (Days -28 to -11)**

Screening procedures, including vital sign assessments, may be repeated no more than 2 times for eligibility purposes. Subjects who are screened but failed to meet inclusion/exclusion criteria (despite potentially having undergone repeated screening assessments, if relevant) may be considered for rescreening with prior written sponsor approval.

For all subjects, the Screening Visit will occur up to 28 days prior to randomization (between Days -28 and -11). The following procedures will be performed at the Screening Visit:

- Obtain informed consent.
- Assess eligibility based on inclusion/exclusion criteria.
- Record demographics and medical/surgical history.
- Record prior medications.
- Perform complete physical examination (general appearance, skin, head, eyes, ears, mouth, oropharynx, neck, heart, lungs, abdomen, extremities, and neuromuscular system).
- Measure height and weight and calculate BMI.
- Perform breath alcohol test.
- Collect urine samples for the following:
  - Urinalysis.
  - Urine drug screen.
- Obtain vital signs (including heart rate, blood pressure, respiration rate, and temperature) while subject is sitting after a minimum 5-minute rest.
- Perform 12-lead ECG (in triplicate approximately 1 minute apart after the subject has been resting in the supine position for at least 10 minutes).

Note: Screening 12-lead ECGs will be printed and will be interpreted as soon as possible by the Investigator or Subinvestigator.

- Collect blood samples for the following:
  - Chemistry, hematology, coagulation, glycosylated hemoglobin and prolactin.
  - FSH (only for females who have been postmenopausal for at least 1 year and are not surgically sterile).
  - TSH.
  - Serum pregnancy test (only for females who are not surgically sterile or postmenopausal for at least 1 year [with confirmed FSH in postmenopausal range]).
  - HIV, HBsAg, and HCV screen.

■ [REDACTED]

#### **6.4 Baseline Gastric Emptying Breath Test Visit (Days -10 to -3)**

Baseline GEBT will be performed between Days -10 and -3 after a minimum 14-day washout from motility agents.

The following procedures will be performed at the Baseline GEBT Visit (Days -10 to -3):

- Assess fasting blood glucose before gastric emptying assessments to ensure a blood glucose of  $\leq 275$  mg/dL.

■ [REDACTED]

- Obtain breath samples for GEBT twice prior to consumption of a standardized,  $^{13}\text{C}$ -enriched meal per the study manual and then at 45, 90, 120, 150, 180, and 240 minutes after meal consumption after an 8-hour fast.
- Record prior medications.
- Obtain vital signs (including heart rate, blood pressure, respiration rate, and temperature) while subject is sitting after a minimum 5-minute rest.

■ [REDACTED]

#### **6.5 Pre-Randomization Visit (Days -3 to -1)**

Pre-randomization procedures will be performed at a separate outpatient visit 1 to 3 days prior to randomization to allow adequate turnaround time for test results. Preferably, the results of the baseline GEBT confirming eligibility would be available prior to the pre-randomization visit procedures; however, there may be instances where the pre-randomization visits occurs on the same day as the GEBT or prior to the results of the baseline GEBT being available. The safety laboratory tests (ie, selected chemistry, hematology, coagulation, and urinalysis as specified below) from this visit will be processed at local laboratories for verifying subject eligibility. Blood

and urine samples for clinical safety laboratory and pregnancy tests will also be sent to the central laboratory for analysis. Eligibility may be based on Screening prolactin test results.

The following procedures will be performed at the pre-randomization visit:

- Assess continued eligibility based on inclusion/exclusion and randomization criteria.
- Record medical/surgical history.
- Record prior medications.
- Collect urine samples for the following:
  - Urinalysis
  - Urine drug screen
  - Collect POC pregnancy test results (only for females who are not surgically sterile or postmenopausal for at least 1 year [with confirmed FSH in postmenopausal range at the Screening Visit]).
- Collect blood samples for the following to be reviewed to confirm randomization eligibility:
  - Chemistry including: ALT, AST, alkaline phosphatase, blood urea nitrogen, creatinine, lipase, sodium, amylase, bicarbonate, creatinine kinase, eGFR, glucose, potassium, total bilirubin  
  
Note: gamma glutamyl transferase, inorganic phosphorous, total protein, albumin, calcium, lactate dehydrogenase, and uric acid levels from Screening will be used to assess randomization eligibility and are not required to be repeated at this visit.
  - Prolactin  
  
Note: Prolactin results from this visit are not required prior to randomization.
  - Hematology including: hematocrit, platelets, white blood cell count and differential, hemoglobin, and red blood cell count.  
  
Note: the glycosylated hemoglobin level from Screening will be used to assess randomization eligibility is not required to be repeated at this visit.  
  
Note: TSH, FSH, HIV/HBsAg/HCV screen will not be repeated.

■ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

## 6.6 Treatment Period – Days 1 to 15

For outpatient visits, subjects will report to the clinic before taking their morning dose of study drug.

### 6.6.1 Day 1 (Randomization)

Eligible subjects will be randomized to receive CIN-102 or placebo. Randomization will occur on the morning of Day 1.

The following procedures will be performed on Day 1:

- Assess continued eligibility based on inclusion/exclusion and randomization criteria.
- Record any new medical/surgical history prior to randomization.
- Record concomitant medications (prior to each dose) and adverse events.
- Perform limited physical examination (minimum of general appearance, skin, heart, lungs, and abdomen).
- Measure weight and calculate BMI using height from the Screening Visit.
- Perform breath alcohol test.
- Collect urine sample for:
  - POC urine drug screen.
- Obtain vital signs (including heart rate, blood pressure, respiration rate, and temperature) while subject is sitting after a minimum 5-minute rest.
- Perform 12-lead ECG [REDACTED]  
[REDACTED]  
[REDACTED]

Note: 12-lead ECGs should be performed in triplicate approximately 1 minute apart after the subject has been resting in the supine position for at least 10 minutes. ECGs performed after the morning dose should be completed  $\pm 15$  minutes from the specified timepoints [REDACTED]  
[REDACTED]

Note: if collection of specific individual PK samples [REDACTED]  
[REDACTED] are not required based on written Sponsor approval, the final ECGs for this visit must be collected when the final PK sample is obtained.

Note: 12-lead ECGs will be printed and will be interpreted as soon as possible by the Investigator. A digital recording of each ECG will be submitted to a central reviewer.

- If the subject continues to meet all eligibility criteria, the subject will be randomized and treatment assigned via IRT.
- Dispense study drug to subject. Administer study drug (all subjects will take a dose of blinded study drug [CIN-102 or placebo capsules] orally at [REDACTED] AM [REDACTED] and [REDACTED] PM [REDACTED]  
[REDACTED]

[REDACTED] Fasting requirements for Day 1 are as follows:

■ [REDACTED]

■ [REDACTED]

- Collect blood samples for the following:
  - Prolactin. Sample collected predose. NOTE: The Day 1 prolactin sample is not required to be repeated if a prolactin was obtained for the pre-randomization visit in the last 72 hours.
  - PK analysis:

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

#### 6.6.2 Day 2

The following procedures will be performed by the subject on Day 2:

- Record concomitant medications and adverse events.

■ [REDACTED]

- Self-administer study drug (all subjects will take a dose of blinded study drug [CIN-102 or placebo capsules] orally at [REDACTED] AM [REDACTED] and [REDACTED] PM [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED])

#### 6.6.3 Day 3 ( $\pm 1$ Day)

The following procedures will be performed as an outpatient visit on Day 3 ( $\pm 1$  day):

- Record concomitant medications and adverse events.
- Collect urine samples for urinalysis.
- Obtain vital signs (including heart rate, blood pressure, respiration rate, and temperature) while subject is sitting after a minimum 5-minute rest.
- Perform 12-lead ECG (in triplicate approximately 1 minute apart after the subject has been resting in the supine position for at least 10 minutes).

Note: 12-lead ECGs will be printed and will be interpreted as soon as possible by the Investigator. A digital recording of each ECG will be submitted to a central reviewer.

- Collect blood samples for the following:
  - Chemistry, hematology, coagulation, and prolactin. Sample collected predose.
  - PK analysis [REDACTED]
- Administer study drug (all subjects will take a dose of blinded study drug [CIN-102 or placebo capsules] orally at [REDACTED] AM [REDACTED] and [REDACTED] PM [REDACTED]  
[REDACTED]  
[REDACTED] The evening dose will be self-administered by the subject.
- Perform study drug accountability.

[REDACTED]

#### 6.6.4 Days 4 to 6

The following procedures will be performed by the subject on Days 4 to 6:

- Record concomitant medications and adverse events.
- [REDACTED]
- Self-administer study drug (all subjects will take a dose of blinded study drug [CIN-102 or placebo capsules] orally at [REDACTED] AM [REDACTED] and [REDACTED] PM [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED])

#### 6.6.5 Day 7 ( $\pm 1$ Day)

The following procedures will be performed as an outpatient visit on Day 7 ( $\pm 1$  days):

- Record concomitant medications and adverse events.
- Collect urine for urinalysis.
- Obtain vital signs (including heart rate, blood pressure, respiration rate, and temperature) while subject is sitting after a minimum 5-minute rest.
- Perform 12-lead ECG (in triplicate approximately 1 minute apart after the subject has been resting in the supine position for at least 10 minutes).

Note: 12-lead ECGs will be printed and will be interpreted as soon as possible by the Investigator. A digital recording of each ECG will be submitted to a central reviewer.

- Collect blood samples for the following:
  - Chemistry, hematology, coagulation, and prolactin. Sample collected predose.
  - PK analysis [REDACTED]
- Administer study drug (all subjects will take a dose of blinded study drug [CIN-102 or placebo capsules] orally at [REDACTED] AM [REDACTED] and self-administer orally at [REDACTED] PM [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED] The evening dose will be self-administered by the subject.
- Perform study drug accountability.

#### 6.6.6 Days 8 to 9

The following procedures will be performed by the subject on Days 8 and 9:

- Record concomitant medications and adverse events.
- Self-administer study drug (all subjects will take a dose of blinded study drug [CIN-102 or placebo capsules] orally at [REDACTED] AM [REDACTED] and [REDACTED] PM [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

#### 6.6.7 Day 10 ( $\pm 1$ Day)

The following procedures will be performed as an outpatient visit on Day 10 ( $\pm 1$  day):

- Record concomitant medications and adverse events.
- Collect urine for urinalysis.
- Obtain vital signs (including heart rate, blood pressure, respiration rate, and temperature) while subject is sitting after a minimum 5-minute rest.

- Perform 12-lead ECG (in triplicate approximately 1 minute apart after the subject has been resting in the supine position for at least 10 minutes).

Note: 12-lead ECGs will be printed and will be interpreted as soon as possible by the Investigator. A digital recording of each ECG will be submitted to a central reviewer.

- Collect blood samples for the following:
  - Chemistry, hematology, coagulation, and prolactin. Sample collected predose.
  - PK analysis [REDACTED]
- Administer study drug (all subject will take a dose of blinded study drug [CIN-102 or placebo capsules] orally at [REDACTED] AM [REDACTED]. Subjects will self-administer study drug [CIN-102 or placebo capsules] orally at [REDACTED] PM [REDACTED]. [REDACTED] The evening dose will be self-administered by the subject.
- Perform study drug accountability.

#### 6.6.8 Days 11 to 13

The following procedures will be performed by the subject on Days 11 to 13:

- Record concomitant medications and adverse events.

- Self-administer study drug (all subjects will take a dose of blinded study drug [CIN-102 or placebo capsules] orally at [REDACTED] AM [REDACTED] and [REDACTED] PM [REDACTED]. [REDACTED] [REDACTED] [REDACTED]

#### 6.6.9 Day 14 (±2 Days)

The following procedures will be performed on Day 14 (±2 days):

- Record concomitant medications and adverse events.
- Collect urine samples for the following:
  - Urinalysis.
  - Urine drug screen.
- Perform complete physical examination (general appearance, skin, head, eyes, ears, mouth, oropharynx, neck, heart, lungs, abdomen, extremities, and neuromuscular system).
- Obtain vital signs (including heart rate, blood pressure, respiration rate, and temperature) while the subject is sitting after a minimum 5-minute rest.

- Perform 12-lead ECG [REDACTED]  
[REDACTED]  
[REDACTED]

Note: 12-lead ECGs should be performed in triplicate approximately 1 minute apart after the subject has been resting in the supine position for at least 10 minutes. ECGs performed after the morning dose should be completed  $\pm 15$  minutes from the specified timepoints [REDACTED]  
[REDACTED]

Note: 12-lead ECGs will be printed and will be interpreted as soon as possible by the Investigator. A digital recording of each ECG will be submitted to a central reviewer.

- Fasting blood glucose will be assessed before study drug administration and gastric emptying assessments to ensure a blood glucose of  $\leq 275$  mg/dL.

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

- Collect blood samples for the following:
  - Chemistry, hematology, coagulation, and prolactin. Sample collected predose.
  - Serum pregnancy test (only for females who are not surgically sterile or postmenopausal for at least 1 year [with confirmed FSH in postmenopausal range at the Screening Visit]).

q [REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]

- Obtain breath samples for GEBT (twice prior to consumption of a standardized,  $^{13}\text{C}$ -enriched meal and then at 45, 90, 120, 150, 180, and 240 minutes after meal consumption).
- Administer study drug (all subjects will take a dose of blinded study drug [CIN-102 or placebo capsules] orally at [REDACTED] AM [REDACTED]  
[REDACTED]

Study drug will be administered and the subject will consume the GEBT meal beginning 30 minutes postdose. The subject will fast for 4 hours after the completion of the GEBT meal.

- Perform study drug accountability and collect unused study drug.

#### 6.6.10 Day 15

The following procedures will be performed as an outpatient visit on Day 15 for all subjects participating in the intensive PK subgroup. Subjects participating in the sparse PK subgroup will have the option to complete either the Day 15 Visit or the Day 16 (+1 day) Visit (ie, if Day 15 is completed, Day 16 (+1 day) is not required):

- Record concomitant medications and adverse events.
- Obtain vital signs (including heart rate, blood pressure, respiration rate, and temperature) while subject is sitting after a minimum 5-minute rest.
- Collect blood sample for PK analysis.
- Perform 12-lead ECG (in triplicate approximately 1 minute apart after the subject has been resting in the supine position for at least 10 minutes).

Note: 12-lead ECGs will be printed and will be interpreted as soon as possible by the Investigator. A digital recording of each ECG will be submitted to a central reviewer.

- For subjects participating in the sparse PK subgroup: collect daily diary materials from subject if applicable. This visit will complete the subject's study participation.

#### 6.6.11 Follow-up Visit (Day 16 [+ 1 Day])

The following procedures will be performed as an outpatient visit on Day 16 (+1 day) for all subjects participating in the intensive PK subgroup and complete the subject's study participation. Subjects participating in the sparse PK subgroup will have the option to complete either the Day 15 Visit or the Day 16 (+1 day) Visit (ie, if Day 15 is completed, Day 16 (+1 day) is not required):

- Record prior and concomitant medications and adverse events.
- Obtain vital signs (including heart rate, blood pressure, respiration rate, and temperature) while subject is sitting after a minimum 5-minute rest.
- Collect blood samples for PK analysis.
- For subjects participating in the sparse PK subgroup perform 12-lead ECG (in triplicate approximately 1 minute apart after the subject has been resting in the supine position for at least 10 minutes).

Note: 12-lead ECGs will be printed and will be interpreted as soon as possible by the Investigator. A digital recording of each ECG will be submitted to a central reviewer.

- Collect daily diary materials from subject if applicable.

## 6.7 Early Termination Visit and Withdrawal Procedures

For subjects who are withdrawn from the study prior to completion, the following procedures will be performed at the Early Termination Visit:

- Obtain breath samples for GEBT (twice prior to consumption of a standardized,  $^{13}\text{C}$ -enriched meal and then at 45, 90, 120, 150, 180, and 240 minutes after meal consumption).
- Record prior and concomitant medications and adverse events.
- Collect urine samples for the following:
  - Urinalysis
  - Urine drug screen
- Perform complete physical examination (general appearance, skin, head, eyes, ears, mouth, oropharynx, neck, heart, lungs, abdomen, extremities, and neuromuscular system).
- Obtain vital signs (including heart rate, blood pressure, respiration rate, and temperature) while subject is sitting after a minimum 5-minute rest.
- Perform 12-lead ECG (in triplicate approximately 1 minute apart after the subject has been resting in the supine position for at least 10 minutes).

Note: 12-lead ECGs will be printed and will be interpreted as soon as possible by the Investigator. A digital recording of each ECG will be submitted to a central reviewer.

- Note: if the subject agrees to perform the GEBT as part of the early-termination visit, the ECG collection procedures specified for the Day 14 ( $\pm 2$  days) Visit will be followed.
- Perform study drug accountability and collect unused study drug.
- Collect blood samples for the following:
  - Chemistry, hematology, coagulation, and prolactin.
  - Serum pregnancy test (only for females who are not surgically sterile or postmenopausal for at least 1 year [with confirmed FSH in postmenopausal range]).
  - PK analysis.
  - Note: if the subject agrees to perform the GEBT as part of the early-termination visit, the PK sample procedures specified for the Day 14 ( $\pm 2$  days) Visit will be followed.

■ [REDACTED] ■ [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]  
[REDACTED]

## 7 EFFICACY ASSESSMENTS

## 7.1 Primary Efficacy Assessment

The primary efficacy variable is the change from baseline (gathered on Days -10 to -3) in gastric emptying as measured by GEBT at Day 14 ( $\pm 2$  days).

The GEPT is a nonradioactive stable isotope breath test, in which the ratio of exhaled  $^{13}\text{CO}_2/^{12}\text{CO}_2$  is used to determine the rate of gastric emptying after consumption of a standardized,  $^{13}\text{C}$ -enriched meal. Subjects will consume a standardized,  $^{13}\text{C}$ -enriched meal after an 8-hour fast at baseline (Days -10 to -3) and after an 8-hour fast starting 30 minutes after study drug administration on Day 14 ( $\pm 2$  days). Breath samples will be obtained twice prior to consumption of a standardized,  $^{13}\text{C}$ -enriched meal and then at 45, 90, 120, 150, 180, and 240 minutes after meal consumption on Days -10 to -3 and Day 14 ( $\pm 2$  days) and 30 minutes after study drug administration on Day 14 ( $\pm 2$  days).

## 7.2 Secondary Efficacy Assessment

The secondary efficacy variables are the following:

- The change from baseline in gastric emptying as measured by GEBT  $T_{1/2}$  (BT  $T_{1/2}$ ) at Day 14 ( $\pm 2$  days)

[REDACTED]

[REDACTED]

### 7.3 Exploratory Efficacy Assessment

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

#### 7.4 Pharmacokinetics

For all subjects, blood samples for PK analysis will be collected at the following visits and timepoints:

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

Subjects may consent to participate in a more intensive PK subgroup. In this subgroup, PK samples will also be collected as follows:

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

Note: in some situations, collection of specific, individual PK samples [REDACTED] may not be required in this subset of subjects with prior written sponsor approval.

[REDACTED]

The following PK parameters will be calculated for deuterated domperidone (and any measured metabolites) using plasma concentrations measured following CIN-102 doses on Day 1 if the data permit:

- $C_{\max}$
- Time to maximum plasma concentration

- AUC 0-12 hours

The following PK parameters will be calculated for deuterated domperidone (and any measured metabolites) using plasma concentrations measured following the final dose of CIN-102, if the data permit:

- $C_{\max}$
- Time to maximum plasma concentration
- AUC over a dosing interval
- AUC from time 0 to the time of the last quantifiable plasma concentration
- AUC from time 0 to infinity
- Percent of AUC extrapolated
- $T_{1/2}$
- Apparent plasma clearance
- Apparent volume of distribution

Trough concentrations collected throughout the study will be used to confirm compliance and attainment of steady-state.

## **7.5 Pharmacogenomic Assessments**

A single, optional PGx blood sample may be collected at any time during the subject's participation in the study. The PGx samples may be used for genetic research to explore the underlying causes of variability and/or differences in response in PK, PD, and/or safety data following administration of CIN-102. Subjects will be given the option to participate in the PGx assessment during the consenting process for the study. In order to have a PGx sample collected, subjects must provide written informed consent to participate, which is included in the main ICF. The subject may withdraw consent to participate in the PGx assessment at any time during the study without withdrawing consent to participate in the study. See Section 7.5.1 for details regarding sample and data destruction following withdrawal of consent. The deoxyribonucleic acid sample will not be immortalized, sold to anyone, or submitted to a public genetic database. The results obtained from analysis of the PGx samples will be accessible to the Sponsor, the party(ies) performing sample and/or data analyses, and the party involved in maintenance of the Sponsor's database. The results may be disclosed to the Investigator but are not intended to be provided to the subject. The PGx results may be reported and/or published without any of the subject's personal identification information.

### **7.5.1 Collection, Storage, and Destruction of Pharmacogenomic Samples**

For subjects who provide written informed consent to participate in the optional PGx assessment, a blood sample will be collected at any time during the subject's participation in the study. The date and time of sample collection will be documented in the subject's source documents. Each sample must be labeled with a unique identifier. Good Laboratory Practice requires a chain of custody that is traceable to the sample donor. To ensure subject confidentiality, sample tubes will be identified by subject identification number only.

Samples will be retained until exhausted or until the Sponsor requests destruction. If the subject withdraws consent, the blood samples will be promptly managed regarding proper disposition. However, the data will not be discarded if genetic analysis has been completed before the subject withdraws consent.

## **8 SAFETY ASSESSMENTS**

### **8.1 Adverse Events**

An adverse event is defined as any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and/or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product whether or not related to the investigational medicinal product. All adverse events, including observed or volunteered problems, complaints, or symptoms, are to be recorded on the appropriate eCRF.

Adverse events, which include clinical laboratory test variables, will be monitored and documented from the time of first dose of study drug until participation is complete. Subjects should be instructed to report any adverse event that they experience to the Investigator and/or relevant site staff whether or not they think the event is due to study treatment. Beginning at the time of first dose of study drug, Investigators should make an assessment for adverse events at each visit and record the event on the appropriate adverse event eCRF.

Wherever possible, a specific disease or syndrome rather than individual associated signs and symptoms should be identified by the Investigator and recorded on the eCRF. However, if an observed or reported sign or symptom is not considered a component of a specific disease or syndrome by the Investigator, it should be recorded as a separate adverse event on the eCRF. Additionally, the condition that led to a medical or surgical procedure (eg, surgery, endoscopy, tooth extraction, or transfusion) should be recorded as an adverse event, not the procedure itself.

Any medical condition already present at the time of first dose of study drug should be recorded as medical history and not be reported as an adverse event unless the medical condition or signs or symptoms present at baseline changes in severity, frequency, or seriousness at any time during the study. In this case, it should be reported as an adverse event.

Clinically significant abnormal laboratory or other examination (eg, ECG) findings that are detected during the study or are present at the time of first dose of study drug and significantly worsen during the study should be reported as adverse events, as described below. The Investigator will exercise his or her medical and scientific judgment in deciding whether an abnormal laboratory finding, or other abnormal assessment is clinically significant. Clinically significant abnormal laboratory values occurring during the clinical study will be followed until repeat tests return to normal, stabilize, or are no longer clinically significant. Abnormal test results that are determined to be an error should not be reported as an adverse event. Laboratory abnormalities or other abnormal clinical findings (eg, ECG abnormalities) should be reported as an adverse event if any of the following are applicable:

- If an intervention is required as a result of the abnormality
- If action with the study drug is required as a result of the abnormality
- Based on the clinical judgment of the Investigator

### 8.1.1 Adverse (Drug) Reaction

All noxious and unintended responses to a medicinal product related to any dose should be considered an adverse drug reaction. “Responses” to a medicinal product means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility, ie, the relationship cannot be ruled out.

### 8.1.2 Unexpected Adverse Drug Reaction

An Unexpected Adverse Drug Reaction is defined as an adverse reaction, the nature or severity of which is not consistent with the applicable product information.

### 8.1.3 Assessment of Adverse Events by the Investigator

The Investigator will assess the severity (intensity) of all adverse events (serious and non-serious) and will be graded using the CTCAE Version 5.0 criteria as shown in Table 1. The Investigator will also categorize each adverse event as to its potential relationship to study drug using the categories of yes or no.

**Table 1. CTCAE Severity Assessment of Adverse Events**

Grade	Severity	Description
1	Mild	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated
2	Moderate	Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living*
3	Severe	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living**
4	Life Threatening	Life threatening consequences; urgent intervention indicated
5	Death	Death related to AE
*Instrumental activities of daily living refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. **Self-care activities of daily living refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.		
Ref: <a href="https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf">https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf</a>		

### Causality assessment:

The relationship of an adverse event to the administration of the study drug is to be assessed according to the following definitions:

No (unrelated, not related, unlikely to be related) – The time course between the administration of study drug and the occurrence or worsening of the adverse event rules out a causal relationship and another cause (concomitant drugs, therapies, complications, etc.) is suspected.

Yes (possibly, probably, or definitely related) – The time course between the administration of study drug and the occurrence or worsening of the adverse event is consistent with a causal

relationship and no other cause (concomitant drugs, therapies, complications, etc.) can be identified.

The definition implies a reasonable possibility of a causal relationship between the event and the study drug. This means that there are facts (evidence) or arguments to suggest a causal relationship.

The following factors should also be considered:

- The temporal sequence from study drug administration-
  - The event should occur after the study drug is given. The length of time from study drug exposure to event should be evaluated in the clinical context of the event.
- Underlying, concomitant, intercurrent diseases-
  - Each report should be evaluated in the context of the natural history and course of the disease being treated and any other disease the subject may have.
- Concomitant drug-
  - The other drugs the subject is taking or the treatment the subject receives should be examined to determine whether any of them might be recognized to cause the event in question.
- Known response pattern for this class of study drug-
  - Clinical and/or preclinical data may indicate whether a particular response is likely to be a class effect.
- Exposure to physical and/or mental stresses-
  - The exposure to stress might induce adverse changes in the recipient and provide a logical and better explanation for the event.
- The pharmacology and PK of the study drug-
  - The known pharmacologic properties (absorption, distribution, metabolism, and excretion) of the study drug should be considered.

## 8.2 Serious Adverse Events

An adverse event or adverse reaction is considered serious if, in the view of either the Investigator or Sponsor, it results in any of the following outcomes:

- Death.
- A life-threatening adverse event.

Note: An adverse event or adverse reaction is considered “life-threatening” if, in view of either the Investigator or Sponsor, its occurrence places the subject at immediate risk of death. It does not include an event that, had it occurred in a more severe form, might have caused death.

- Requires hospitalization or prolongation of existing hospitalizations.

Note: Any hospital admission with at least 1 overnight stay will be considered an inpatient hospitalization. An emergency room or urgent care visit without hospital admission will not be recorded as a SAE under this criterion, nor will hospitalization for a procedure scheduled

or planned before signing of informed consent, or elective treatment of a pre-existing condition that did not worsen from Baseline. However, unexpected complications and/or prolongation of hospitalization that occur during elective surgery should be recorded as adverse events and assessed for seriousness. Admission to the hospital for social or situational reasons (ie, no place to stay, live too far away to come for hospital visits, respite care) will not be considered inpatient hospitalizations.

- A persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions.
- A congenital anomaly/birth defect.
- An important medical event.

Note: Important medical events that do not meet any of the above criteria may be considered an SAE when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent 1 of the outcomes listed above. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalizations, or the development of drug dependency.

### 8.3 Serious Adverse Event Reporting – Procedures for Investigators

#### Initial Reports

All SAEs occurring from the time of first dose of study drug until 30 days following the final dose of study drug must be reported to [REDACTED] within 24 hours of the knowledge of the occurrence. After the 30-day reporting window, any SAE that the Investigator considers related to study drug must be reported to [REDACTED] or the Sponsor/designee. Of note, reporting of SAEs after the follow-up phone call 72 hours after discharge is dependent on spontaneous reporting by the subject. The Investigator is not required to have further contact to elicit this information after completion of the follow-up phone call but should instruct the subject to contact the site to report any such events.

To report the SAE, complete the SAE form electronically in the electronic data capture (EDC) system for the study. When the form is completed, [REDACTED] personnel will be notified electronically by the EDC system and will retrieve the form. If the event meets serious criteria and it is not possible to access the EDC system, send an e-mail to [REDACTED] at [REDACTED] or call the (b) [REDACTED] reporting line (phone number listed below), and fax/e-mail the completed paper SAE form to [REDACTED] (fax number listed below) within 24 hours of awareness. When the EDC system becomes available, the SAE information must be entered within 24 hours of the system becoming available.

Safety Contact Information: [REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

#### Follow-Up Reports

The Investigator must continue to follow the subject until the SAE has subsided or until the condition becomes chronic in nature, stabilizes (in the case of persistent impairment), or the subject dies.

Within 24 hours of receipt of follow-up information, the Investigator must update the SAE form electronically in the EDC system for the study and submit any supporting documentation (eg, patient discharge summary or autopsy reports) to [REDACTED] via fax or e-mail. If it is not possible to access the EDC system, refer to the procedures outlined above for initial reporting of SAEs.

#### **8.4 Pregnancy Reporting**

If a subject becomes pregnant during the study or within the safety follow-up period defined in the protocol, the Investigator is to stop dosing with study drug(s) immediately and the subject should be withdrawn from the study. Early termination procedures should be implemented at that time.

A pregnancy is not considered to be an adverse event or SAE; however, it must be reported to [REDACTED] within 24 hours of knowledge of the event. [REDACTED] will then provide the Investigator/site the Exposure In Utero (EIU) form for completion. The Investigator/site must complete the EIU form and fax or e-mail it back to [REDACTED]

If the female partner of a male subject becomes pregnant while the subject is receiving study drug or within the safety follow-up period defined in the protocol, the Investigator should notify [REDACTED] as described above.

The pregnancy should be followed until the outcome of the pregnancy, whenever possible. Once the outcome of the pregnancy is known, the EIU form should be completed and faxed/e-mailed to [REDACTED]. If the outcome of the pregnancy meets the criteria for immediate classification as an SAE (ie, postpartum complication, spontaneous abortion, stillbirth, neonatal death, or congenital anomaly), the Investigator should follow the procedures for reporting an SAE.

#### **8.5 Expedited Reporting**

The Sponsor will report all relevant information about suspected unexpected serious adverse reactions that are fatal or life-threatening as soon as possible to the FDA and in any case no later than 7 days after knowledge by the Sponsor/designee of such a case, and the relevant follow-up information will subsequently be communicated within an additional 8 days.

All other suspected unexpected serious adverse reactions will be reported to the FDA as soon as possible but within a maximum of 15 days of first knowledge by the Sponsor/designee.

The Sponsor/designee will also inform all Investigators as required.

#### **8.6 Clinical Laboratory Evaluations**

Safety laboratory tests will include chemistry, hematology, coagulation, prolactin, and urinalysis. See [Appendix B](#) for a complete list of analytes.

Safety laboratory tests will be evaluated at the times indicated in the Schedule of Procedures table in [Appendix A](#).

Abnormal screening laboratory tests may be repeated no more than 2 times for eligibility purposes.

If, in the opinion of the Investigator, any subject has a clinically significant abnormal laboratory finding in comparison to the value at the time of randomization or unresolved TEAEs, additional follow-up visits will be scheduled. Subjects will be followed approximately once a week (or more frequently as deemed appropriate) until the Investigator determines that repeat laboratory findings are clinically unremarkable in comparison to baseline, or unresolved adverse events return to prestudy levels or clinically acceptable levels.

If a subject experiences an SAE for which follow-up laboratories and review are required, the Investigator will schedule additional postdose visits as necessary.

If, in the opinion of the Investigator, any subject has a clinically significant adverse event at the follow-up call, the Investigator will provide additional follow-up until the adverse event returns to clinically acceptable levels.

The safety laboratory sample collection times may be refined based on emerging data to ensure study objectives are met.

## **8.7 Vital Signs**

Vital signs, including heart rate, blood pressure, respiration rate, and temperature, will be measured at the times indicated in the [Schedule of Procedures table](#) in Appendix A using the following standardized procedures:

- Prior to measuring vital signs, the subject should be sitting for a minimum of 5 minutes with his/her back supported, feet flat on the floor, and his/her measurement arm supported so that the midpoint of the manometer cuff is at heart level.
- An appropriately sized cuff should be used with the bladder centered over the brachial artery.
- The cuff size and arm used for the measurement should be recorded. Whenever possible, the same arm should be used for all vital sign assessments throughout the study.
- Blood pressure should be recorded to the nearest whole number on an automatic device.

## **8.8 Electrocardiograms**

Twelve-lead ECGs will be performed at the times indicated in the Schedule of Procedures table in Appendix A.

Every effort will be made to eliminate any sources of physical (including any movement, eating, or drinking) or electrical interference. During these assessments, subjects are not permitted to use cell phones, iPods, laptop computers, tablets, or any type of battery-operated or electrical device, and all of these devices must be turned off during the assessments.

All 12-lead ECGs will be performed in triplicate approximately 1 minute apart after the subject has been resting in the supine position for at least 10 minutes. The average QTcF will be used for eligibility and safety assessments. Twelve-lead ECGs will be printed and will be interpreted as soon as possible by an Investigator (or Subinvestigator for Screening Visit only). All ECGs collected at the time of randomization and throughout the treatment period must be evaluated for the presence of abnormalities by a qualified physician. A digital recording of all ECGs for randomized subjects will be submitted to a central reviewer. The central overread ECG data will be utilized for all safety assessments and analyses.

Standard ECG parameters will be measured, and the following ECG parameters will be recorded:

- QRS interval
- Heart rate
- RR interval
- QT interval
- QTc (QTcF)

Investigators should contact the Sponsor or designee if any clinically meaningful changes from baseline are noted on review. Please refer to [Appendix C](#) for ECG alert criteria guidance.

## **8.9 Physical Examinations**

Complete physical examinations will be performed at the times indicated in the [Schedule of Procedures table](#) in Appendix A. A complete physical examination will consist of general appearance, skin, head, eyes, ears, mouth, oropharynx, neck, heart, lungs, abdomen, extremities, and neuromuscular system.

Brief limited physical examinations will be performed at the times indicated in the Schedule of Procedures table in Appendix A. A limited physical examination will consist of a minimum of general appearance, skin, heart, lungs, and abdomen.

All complete and limited physical examination findings must be recorded.

## **8.10 Height and Weight**

Height and weight will be measured at the times indicated in the Schedule of Procedures table in Appendix A and will be used to calculate BMI. Height will be measured with the subject's shoes off. Weight will be measured with the subject's shoes off and after the subject's bladder has been emptied.

## 9 STATISTICS

## 9.1 Analysis Populations

The Intent-to-Treat Population will include all randomized subjects.

The Modified Intent-to-Treat (MITT) Population will include all randomized subjects who receive at least 1 dose of study drug.

The Per-Protocol (PP) Population will include all subjects in the MITT Population without major protocol violations. Reasons for excluding subjects from the PP Population and will be described in detail in the Statistical Analysis Plan.

The PK Population will include all subjects who receive at least 1 dose of CIN-102 and have at least 1 quantifiable postdose plasma CIN-102 concentration.

The PK Evaluable Population will include subjects who receive CIN-102 and have sufficient plasma concentration data to characterize at least 1 PK parameter.

The PD Population will include all subjects who receive study drug and have at least 1 prolactin value following the start of study drug administration.

The Safety Population will consist of all randomized subjects who receive any study drug.

## 9.2 Statistical Methods

The data from placebo subjects of all cohorts will be pooled for efficacy and safety analysis.

### 9.2.1 Analysis of Efficacy

[illegible]

#### 9.2.1.4 Pharmacokinetic analysis

The CIN-102 plasma concentrations and PK parameters will be listed by individual and summarized by treatment for active treatments in tabular format using descriptive statistics. CIN-102 plasma concentrations will be plotted against timepoints by regimen (mean and individual).

#### 9.2.1.5 Pharmacokinetic-Pharmacodynamic analysis

If the data permit, an attempt will be made to correlate plasma concentration and/or PK parameters with select safety measures, prolactin data, and/or measures of gastric emptying time and symptoms of gastroparesis.

#### 9.2.2 Analysis of Safety

Safety data, including physical examinations, ECGs, vital sign assessments, clinical laboratory evaluations (including prolactin), and adverse events, will be summarized by treatment group and time of collection, when appropriate. Individual and mean time course of absolute prolactin values and change from baseline prolactin by treatment may also be generated.

Descriptive statistics (arithmetic mean, standard deviation, median, minimum, and maximum) will be calculated for quantitative safety data, as well as for the difference from baseline, when appropriate. Absolute and change from baseline values in QT (using QTcF) will be plotted against timepoints by treatment, if applicable. The central overread ECG data will be utilized for all safety assessments and analyses.

Shift tables describing out-of-normal range shifts will be provided for clinical laboratory results.

#### 9.2.3 Interim Analysis

An independent DRC will review emerging safety, PK, and/or efficacy data throughout the study to determine if it is safe and appropriate to continue the study with the currently planned dose levels for Cohorts 2 and 3 or if further refinement of the proposed dose levels is warranted. The DRC will also determine how to advance the cohorts. Further details regarding the role, responsibilities, and procedures of the DRC will be provided in the DRC Charter.

#### 9.2.4 Sample Size Determination

A total of 60 subjects (15 subjects per treatment) will be randomized to CIN-102 [REDACTED] BID, CIN-102 [REDACTED] BID, CIN-102 [REDACTED] BID, or placebo. The sample size is considered adequate to provide the necessary data to evaluate the objectives of the study. No formal statistical assessment for sample size determination has been performed.

## **10 DATA MANAGEMENT AND RECORD KEEPING**

### **10.1 Data Management**

#### **10.1.1 Data Handling**

Data will be recorded at the site on eCRFs and reviewed by the clinical research associate (CRA) during monitoring visits. The CRAs will verify data recorded in the EDC system with source documents. All corrections or changes made to any study data must be appropriately tracked in an audit trail in the EDC system. An eCRF will be considered complete when all missing, incorrect, and/or inconsistent data has been accounted for.

#### **10.1.2 Computer Systems**

Data will be processed using a validated computer system conforming to regulatory requirements.

#### **10.1.3 Data Entry**

Data must be recorded using the EDC system as the study is in progress. All site personnel must log into the system using their secure username and password in order to enter, review, or correct study data. These procedures must comply with Title 21 of the Code of Federal Regulations (21 CFR Part 11) and other appropriate international regulations. All passwords will be strictly confidential.

#### **10.1.4 Medical Information Coding**

For medical information, the following thesauri will be used:

- Medical Dictionary for Regulatory Activities (latest) for medical history and adverse events
- World Health Organization Drug Dictionary for prior and concomitant medications

#### **10.1.5 Data Validation**

Validation checks programmed within the EDC system, as well as supplemental validation performed via review of the downloaded data, will be applied to the data in order to ensure accurate, consistent, and reliable data. Data identified as erroneous, or data that are missing, will be referred to the investigative site for resolution through data queries.

The eCRFs must be reviewed and electronically signed by the Investigator.

### **10.2 Record Keeping**

Records of subjects, source documents, monitoring visit logs, eCRFs, inventory of study product, regulatory documents, and other Sponsor correspondence pertaining to the study must be kept in the appropriate study files at the site. Source data is defined as all information in original records and certified copies of original records of clinical findings, observations, or other activities in a clinical study necessary for the evaluation and reconstruction of the clinical study. Source data are contained in source documents (original records or certified copies). These records will be retained in a secure file for the period as set forth in the Clinical Study Agreement. Prior to transfer or destruction of these records, the Sponsor must be notified in writing and be given the opportunity to further store such records.

## **11 INVESTIGATOR REQUIREMENTS AND QUALITY CONTROL**

### **11.1 Ethical Conduct of the Study**

Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting studies that involve human subjects. Compliance with this standard provides public assurance that the rights, safety, and well-being of study subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical study data are credible.

### **11.2 Institutional Review Board**

The Institutional Review Board (IRB) will review all appropriate study documentation in order to safeguard the rights, safety, and well-being of subjects. The study will only be conducted at sites where IRB approval has been obtained. The protocol, Investigator's Brochure, ICF, advertisements (if applicable), written information given to the subjects, safety updates, annual progress reports, and any revisions to these documents will be provided to the IRB by the Investigator.

Federal regulations and International Council for Harmonisation (ICH) Guidelines require that approval be obtained from an IRB prior to participation of subjects in research studies. Prior to study onset, the protocol, any protocol amendments, ICFs, advertisements to be used for subject recruitment, and any other written information regarding this study to be provided to a subject or subject's legal guardian must be approved by the IRB.

No drug will be released to the site for dosing until written IRB authorization has been received by the Sponsor.

### **11.3 Informed Consent**

The ICF and any changes to the ICF made during the course of the study must be agreed to by the Sponsor or designee and the IRB prior to its use and must be in compliance with all ICH GCP, local regulatory requirements, and legal requirements.

The Investigator must ensure that each study subject is fully informed about the nature and objectives of the study and possible risks associated with participation and must ensure that the subject has been informed of his/her rights to privacy. The Investigator will obtain written informed consent from each subject before any study-specific activity is performed and should document in the source documentation that consent was obtained prior to enrollment in the study. The original signed copy of the ICF must be maintained by the Investigator and is subject to inspection by a representative of the Sponsor, their representatives, auditors, the IRB, and/or regulatory agencies. A copy of the signed ICF will be given to the subject.

### **11.4 Study Monitoring Requirements**

It is the responsibility of the Investigator to ensure that the study is conducted in accordance with the protocol, Declaration of Helsinki, ICH GCP, and applicable regulatory requirements, and that valid data are entered into the eCRFs.

To achieve this objective, the CRA's duties are to aid the Investigator and, at the same time, the Sponsor in the maintenance of complete, legible, well-organized and easily retrievable data. Before the enrollment of any subject in this study, the Sponsor or their designee will review with the Investigator and site personnel the following documents: protocol, Investigator's Brochure, eCRFs

and procedures for their completion, informed consent process, and the procedure for reporting SAEs.

The Investigator will permit the Sponsor or their designee to monitor the study as frequently as deemed necessary to determine that data recording and protocol adherence are satisfactory. During the monitoring visits, information recorded on the eCRFs will be verified against source documents and requests for clarification or correction may be made. After the eCRF data is entered by the site, the CRA will review the data for safety information, completeness, accuracy, and logical consistency. Computer programs that identify data inconsistencies may be used to help monitor the clinical study. If necessary, requests for clarification or correction will be sent to the Investigators. The Investigator and his/her staff will be expected to cooperate with the monitor and provide any missing information, whenever possible.

All monitoring activities will be reported and archived. In addition, monitoring visits will be documented at the investigational site by signature and date on the study-specific monitoring log.

### **11.5 Disclosure of Data**

Data generated by this study must be available for inspection by the FDA, the Sponsor or their designee, applicable foreign health authorities, and the IRB as appropriate. Subjects or their legal representatives may request their medical information be given to their personal physician or other appropriate medical personnel responsible for their welfare.

Patient medical information obtained during the study is confidential and disclosure to third parties other than those noted above is prohibited.

### **11.6 Retention of Records**

To enable evaluations and/or audits from regulatory authorities or the Sponsor, the Investigator will keep records, including the identity of all participating subjects (sufficient information to link records; eg, eCRFs and hospital records), all original signed ICFs, copies of all eCRFs, SAE forms, source documents, and detailed records of treatment disposition. The records should be retained by the Investigator according to specifications in the ICH guidelines, local regulations, or as specified in the Clinical Study Agreement, whichever is longer. The Investigator must obtain written permission from the Sponsor before disposing of any records, even if retention requirements have been met.

If the Investigator relocates, retires, or for any reason withdraws from the study, the Sponsor should be prospectively notified. The study records must be transferred to an acceptable designee, such as another Investigator, another institution, or to the Sponsor.

### **11.7 Publication Policy**

Following completion of the study, the data may be considered for publication in a scientific journal or for reporting at a scientific meeting. Each Investigator is obligated to keep data pertaining to the study confidential. The Investigator must consult with the Sponsor before any study data are submitted for publication. The Sponsor reserves the right to deny publication rights until mutual agreement on the content, format, interpretation of data in the manuscript, and journal selected for publication are achieved.

## **11.8 Financial Disclosure**

Investigators are required to provide financial disclosure information to the Sponsor to permit the Sponsor to fulfill its obligations under 21 CFR Part 54. In addition, Investigators must commit to promptly updating this information if any relevant changes occur during the study and for a period of 1 year after the completion of the study.

## **12 STUDY ADMINISTRATIVE INFORMATION**

### **12.1 Protocol Amendments**

Any amendments to the study protocol will be communicated to the Investigators by [REDACTED] or the Sponsor. All protocol amendments will undergo the same review and approval process as the original protocol. A protocol amendment may be implemented after it has been approved by the IRB, unless immediate implementation of the change is necessary for subject safety. In this case, the situation must be documented and reported to the IRB within 5 working days.

## 13 REFERENCES

1. Bielefeldt K. Gastroparesis: concepts, controversies, and challenges. *Scientifica (Cairo)*. 2012;2012:424802.
2. Parkman HP, Jacobs MR, Mishra A, et al. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. *Dig Dis Sci*. 2011;56(1):115-124.
3. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Gastroparesis: clinical evaluation of drugs for treatment. Guidance for industry [draft guidance]. July 2015.
4. Camilleri M, Bharucha AE, Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. *Clin Gastroenterol Hepatol*. 2011;9(1):5-12.
5. Ortiz A, Cooper CJ, Alvarez A, et al. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. *Am J Med Sci*. 2015;349(5):421-424.
6. [REDACTED]
7. Motilium® (domperidone) [product information]. Macquarie Park, NSW, Australia. Janssen-Cilag Pty Ltd. 04 February 2019.
8. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. *Am J Gastroenterol*. 2007;102(9):2036-2045.
9. Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. *Am J Gastroenterol*. 2013;108(1):18-37.
10. Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. *J Psychopharmacol*. 2008;22(2 Suppl):12-19.
11. Buffery PJ, Strother RM. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. *N Z Med J*. 2015;128(1416):66-74.
12. European Medicines Agency, Pharmacovigilance Risk Assessment Committee (PRAC). Assessment report. Domperidone-containing medicinal products. March 2014.
13. FDA Briefing Document (Domperidone). Pharmacy Compounding Advisory Committee Meeting. October 2015.
14. Biewenga J, Keung C, Solanki B, et al. Absence of QTc prolongation with domperidone: a randomized, double-blind, placebo- and positive-controlled thorough QT/QTc study in healthy volunteers. *Clin Pharmacol Drug Dev*. 2015;4(1):41-48.
15. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Guidance for Industry. October 2005.
16. Motilium® (domperidone) [datasheet]. Auckland, New Zealand. Janssen-Cilag (New Zealand) Ltd. 02 May 2016.
17. Food and Drug Administration, Center for Drug Evaluation and Research. Pharmacy Compounding Advisory Committee (PCAC) Meeting transcript. 28 October 2015.

18. Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. *Br J Clin Pharmacol*. 2012;73(3):411-421.
19. US Food and Drug Administration. How to request domperidone for expanded access use.  
<https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/investigationalnewdrugindapplication/ucm368736.htm>. Accessed 09 August 2018.
20. Bharucha AE, Camilleri, M, Veil, E. Comprehensive assessment of gastric emptying with a stable isotope breath test. *Neurogastroenterol Motil*. 2013;25(1).

## APPENDIX A: SCHEDULE OF PROCEDURES

**Table 2. Schedule of Procedures**

Study Day	Screening	Baseline	Pre-	Treatment Period															Follow
	-28 to -11	GEBT [16] -10 to -3	Randomization -3 to -1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15 [22]	16 [22]
Visit Window (Days)						±1				±1			±1				±2		+1
Clinic Visit Day	X	X	X	X		X				X			X				X	X	X
<b>PK Sampling Details</b>																			
Multiple PK sample [1]				X													X		
Single PK sample [2]						X				X			X					X [2,23]	
<b>Procedure</b>																			
Informed consent [3]	X																		
I/E criteria [4]	X		X	X															
Randomization criteria				X															
Demographics	X																		
Medical/surgical history	X		X	X															
Prior and concomitant medications [5]	← X →																		
Adverse events [6]	← X →																		
Complete physical examination [7]	X																X		
Limited physical examination [7]				X															
Weight and height [8]	X			X[8]															
Vital signs [9]	X	X	X	X		X				X			X				X	X[23]	X
Breath alcohol test	X			X															
Urine drug screen	X		X	X[11]													X		
Urinalysis	X		X			X				X			X				X		
HIV/HBsAg/HCV screen	X																		
FSH [10]	X																		
TSH	X																		
Pregnancy test [12]	X		X[12]														X		
12-lead ECG [13]	X			X [14]		X				X			X				X [14]	X[23]	
GEBT [15]		X															X		

See footnotes at the end of the table on the following page.

**Table 2. Schedule of Procedures (Continued)**

Study Day Visit Window (Days)	Screening	Baseline GEBT [16]	Pre- Randomization	Treatment Period																Follow- up
	-28 to -11	-10 to -3	-3 to -1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15 [22]	16 [22]	
						±1				±1			±1				±2		+1	
Chemistry, hematology, and coagulation	X		X			X				X			X				X			
Glycosylated hemoglobin	X																			
Prolactin [17]	X		X	X[17]		X				X			X				X			
Randomize Subject				X																
Dispense study drug [18]				X																
Study drug administration [19]				X	X	X	X	X	X	X	X	X	X	X	X	X	X			
Study drug accountability and collection of unused study drug [20]						X				X			X				X			
Collection of electronic diary materials																		X[23]		
PGx sample (optional) [21]	← X →																			
Note: All days will be reported as the next nominal day in sequential order (ie, if the outpatient visit Day 3 [±1 Day] takes place on the sequential Day 4, it will be recorded as Day 4. All following days will be recorded likewise).																				
1. On Day 1, all subjects will be confined to the clinic [REDACTED] Blood samples for PK analysis will be collected from all subjects [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]																				
2. On Days 3 (±1 day), 7 (±1 day), and 10 (±1 day), all subjects will report to the clinic for an outpatient visit. Blood samples for PK analysis will be taken prior to the morning dose of study drug (within 5 minutes). Subjects in the intensive PK subgroup will report to the clinic on the day following their last dose of study drug (Day 15) and on Day 16 (+1 day) and a PK sample will be collected at each visit. Subjects in the sparse PK subgroup may report to the clinic on either Day 15 or Day 16 (+1 day) and a PK sample will be collected at this visit.																				
3. Written informed consent for the study will be obtained from all subjects before any study procedures are performed.																				

4. Screening procedures, including vital sign assessments, may be repeated no more than 2 times for eligibility purposes.
5. Any medications administered 28 days prior to the first dose of study drug and during the study period must be recorded. Starting on Day 1, concomitant medications will be recorded by the subject prior to each dose and recorded by the Investigator at each outpatient visit prior to each dose.
6. Adverse events will be monitored and documented by the subject and by the Investigator at each outpatient visit from the time first dose of study drug until study participation is complete.
7. A complete physical examination will consist of general appearance, skin, head, eyes, ears, mouth, oropharynx, neck, heart, lungs, abdomen, extremities, and neuromuscular system. A limited physical examination will consist of a minimum of general appearance, skin, heart, lungs, and abdomen.
8. Height will be measured at the Screening Visit only. Body mass index will be calculated at the Screening Visit using height and weight collected at the Screening Visit. At the time of randomization (Day 1), BMI will be calculated using weight from the time of randomization (Day 1) and height from the Screening Visit.
9. Vital signs including heart rate, blood pressure, respiration rate, and temperature and will be collected while subject is sitting after a minimum 5-minute rest.
10. Follicle-stimulating hormone will only be measured for females who have been postmenopausal for at least 1 year and are not surgically sterile.
11. At the time of randomization (Day 1), a POC drug test will be performed for use in assessing eligibility. A urine sample will also be sent to the central lab for confirmatory testing.
12. A pregnancy test will only be performed in females who are not surgically sterile (or postmenopausal for at least 1 year [with confirmed FSH in postmenopausal range at the Screening Visit]). A serum pregnancy test will be performed by the central lab on Days -28 to -11 and Day 14 ( $\pm 2$  days). A POC pregnancy test will initially be performed on the Day -3 to -1 visit for use in assessing randomization eligibility.
13. All 12-lead ECGs will be performed in triplicate approximately 1 minute apart after the subject has been resting in the supine position for at least 10 minutes. Twelve-lead ECGs will be printed and will be interpreted as soon as possible by an Investigator (or Subinvestigator for Screening Visit only). A digital recording of all ECGs from randomized subjects will be submitted to a central reviewer. ECGs should be completed  $\pm 15$  minutes from all specified time points.
14. On Days 1 and 14 ( $\pm 2$  days), ECGs will be performed prior to the morning dose and [REDACTED] hours (as applicable) after the morning dose and should be completed  $\pm 15$  minutes from the specified timepoints. For subjects participating in the intensive PK, additional ECGs will be performed at [REDACTED] (if applicable) after the morning dose). Note: if collection of specific individual PK samples (including but not limited to the samples at [REDACTED] for the intense PK subgroup) are not required based on written Sponsor approval, the final ECGs for these visits must be collected when the final PK sample is obtained. See [Appendix C](#) for ECG review criteria guidance.
15. Subjects will have baseline GEBT performed between Days -10 and -3 after a minimum 14-day washout from motility agents and on Day 14 ( $\pm 2$  days) 30 minutes after study drug administration. Subjects will fast for a minimum of 8 hours before the breath test. Breath samples will be obtained twice prior to consumption of a standardized,  $^{13}\text{C}$ -enriched meal and then on Day 1 at 45, 90, 120, 150, 180, and 240 minutes post-meal an 8-hour fast on Days -10 to -3 and on Day 14 ( $\pm 2$  days) at 45, 90, 120, 150, 180, and 240 minutes starting 30 minutes after study drug administration. Fasting glucose will be assessed before GEBT to ensure a blood glucose level of  $\leq 275$  mg/dL.
16. [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]
17. Sample collected predose. The Day 1 prolactin sample is not required to be repeated if a prolactin was obtained for the pre-randomization visit in the last 72 hours.
18. Study drug will be dispensed with treatment assigned via IRT on Day 1.
19. All subjects will take a dose of blinded study drug (CIN-102 or placebo capsules) orally at [REDACTED] AM [REDACTED] and [REDACTED] PM [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

- The evening dose will be self-administered by the subject. If a subject reports vomiting during the treatment period, subjects should attempt to note the time of vomiting in relation to time of study drug administration and report this to site staff during scheduled clinic visits.
20. Study drug accountability will occur on Days 3, 7, 10, and 14 or on Early Termination if applicable. Unused study drug will only be collected on Day 14 ( $\pm 2$  days) or on Early Termination if applicable.
  21. For subjects who provide written informed consent to participate in the optional PGx assessment, a blood sample will be collected at any time during the subject's participation in the study.
  22. Subjects participating in the intensive PK subgroup will report to the clinic on Day 15 and on Day 16 (+1 day) where a PK sample will be collected at each respective visit. Subjects in the sparse PK subgroup may report to the clinic on either Day 15 or Day 16 (+1 day) and a PK sample will be collected at the selected visit.
  23. For subjects participating in the sparse PK subgroup and are only required to be complete either Day 15 or Day 16 (+1 day) these procedures will be performed on Day 16 (+1 day) if Day 15 was not performed. Note: electronic diary materials will only be collected if provided to the subject by the Sponsor as applicable.

ECG = electrocardiogram; ET = early termination; FSH = follicle-stimulating hormone; GEBT = gastric emptying breath test; HBsAg = Hepatitis B surface antigen; HCV = Hepatitis C virus; HIV = human immunodeficiency virus; I/E = inclusion and exclusion; POC = point of care, Severity Index; PK = pharmacokinetic; PGx = pharmacogenomic; TSH = thyroid-stimulating hormone.

## APPENDIX B: CLINICAL LABORATORY ANALYTES

### Standard Safety Chemistry Panel

Alanine aminotransferase	Albumin
Alkaline phosphatase	Amylase
Aspartate aminotransferase	Bicarbonate
Blood urea nitrogen	Calcium
Chloride	Creatine kinase
Creatinine	Estimated glomerular filtration rate
Gamma-glutamyl transferase	Glucose
Inorganic phosphorus	Lactate dehydrogenase
Lipase	Potassium
Sodium	Total bilirubin
Total protein	Uric acid

### Endocrinology

Follicle-stimulating hormone [1]	Prolactin
Thyroid-stimulating hormone	

1. Follicle-stimulating hormone will only be assessed in females who have been postmenopausal for at least 1 year and are not surgically sterile.

### Hematology

Hematocrit	Hemoglobin
Platelets	Red blood cell count
Glycosylated hemoglobin	
White blood cell count and differential [1]	

1. Manual microscopic review is performed only if white blood cell count and/or differential values are out of reference range.

### Urinalysis

Bilirubin	Blood
Glucose	Ketones
Leukocyte esterase	Microscopy [1]
Nitrite	pH
Protein	Specific gravity
Urobilinogen	

1. Microscopy is performed only as needed based on positive dipstick results.

### Serology

Hepatitis B surface antigen	Hepatitis C virus antibody
Human immunodeficiency virus antibody	

### Pregnancy Test

Serum and point-of-care pregnancy tests will only be performed in females who are not surgically sterile (or postmenopausal for at least 1 year [with confirmed FSH in postmenopausal range at the Screening Visit]).

### Urine Drug Screen [1]

Amphetamines	Cocaine
Cotinine	Opiates
Phencyclidine	Tetrahydrocannabinol
1. Urine drug screen point of care drug test on randomization day.	

### Breath Alcohol Test

## **APPENDIX C: ELECTROCARDIOGRAM ALERT CRITERIA GUIDANCE**

**Investigators should contact the Sponsor or designee if any clinically meaningful changes from baseline ECGs, including but not limited to those listed below, are noted upon review.**

- QTcF  $\geq 450$  msec (male)
- QTcF  $\geq 470$  msec (female)
- A  $> 60$  msec increase in QTcF from baseline
- A 6% or greater increase in QTcF from baseline

**New onset findings including but not limited to the following:**

- Second degree AV block (Mobitz II)
- Third degree AV block (complete heart block)
- Acute myocardial infarction
- New left bundle branch block (LBBB)
- Severe bradycardia (ventricular rate  $\leq 40$  bpm)
- Supraventricular tachycardia (SVT) (ventricular rate  $\geq 150$  bpm)
- Torsades de pointes
- Ventricular tachycardia (Three or more beats regardless of rate)
- Ventricular fibrillation
- Atrial fibrillation/atrial flutter (ventricular rate  $\geq 150$  bpm)